Google
 

Article Index
HIV Drug and Treatment
General
- Changing Antiretroviral Therapy: Why, When, and How
- Nutrition and HIV
Fuzeon
- Introduction: Why Do We Need a New Class of HIV Medications?
- Entry Inhibitors: A New Class of HIV Medications
- How Does Fuzeon Work?
- What We Know About Fuzeon
- Who Fuzeon Works Best For
- Fuzeon's Side Effects
- Conclusion: Fuzeon's Role in Treatment
- Ten Tips on Injecting Fuzeon
- FUZEON: avoiding injection-site reactions
Alternative
- Could green tea prevent HIV?
- Ayurvedic Management of HIV/AIDS

News
- Scouts get the HIV message
- Perspectives on Asia Pacific AIDS conference
-
Myanmar: Towards universal access
-
Orphans with HIV/AIDS and Family Health and Wellness Programs to Benefit from Constella's Enhancing Human Health Grants
- Foods debunked as alternatives to AIDS meds
- Thailand HIV/AIDS Situation
- Kenya: HIV Patients Suffer As Drug is Recalled
- Niger's Religious Leaders Form Alliance To Prevent Spread Of HIV
- Morality Gets a Massage
-
An African Solution
- Greytown Hospital Kept Open with Help of Umvoti AIDS Centre Volunteers
- Guangdong faces severe HIV situation
- UN corrects itself, India’s HIV situation isn’t that bad
- New AIDS figures show low prevalence (India)
- The Sydney Declaration: Good Research Drives Good Policy and Programming - A Call to Scale Up Research
- Million more AIDS deaths forecast in South Africa by 2010
- Brazilian President Silva Issues Compulsory License for Merck's Antiretroviral Efavirenz
- FDA Approves First Oral Fluid Based Rapid HIV Test Kit
- HIV/AIDS funding gap could hit 50% by 2007: U.N. agency

Miscellaneaus
- Red ribbon history
- HIV and AIDS in africa
-
Dr Krisana Kraisintu first used her pharmaceutical expertise to make HIV/Aids treatment affordable in Thailand, then she moved on to Africa
- Speech at Harward by Bill Gates
- Quit complain in
- Urban action networks; HIV/AIDS and community organizing in New York City
- Living With HIV
Showing posts with label HIV drug and treatment. Show all posts
Showing posts with label HIV drug and treatment. Show all posts

2008/08/22

Ayurvedic Management of HIV/AIDS

Article sources : http://www.articlecity.com/
by: Dr AbdulMubeen A Mundewadi

At present, there is no scientifically proved cure for HIV /AIDS. Globally, the number of infected HIV /AIDS patients is increasing at an alarming rate; with a current estimate of 33.2 million people who are living with HIV 1. Hence, there is a dire need to search for a safe, effective and economical treatment for HIV /AIDS.

In a retrospective study in 55 patients, Ayurvedic treatment has proved to be very promising in the management of HIV/AIDS. Fifty-Five adult patients were given Ayurvedic treatment for HIV/AIDS, during the period from April 1999 to November 2004.Each patient had tested positive for HIV/AIDS on at least 2 different occasions. No patient was taking anti-retroviral drugs at the time of commencing Ayurvedic treatment. All patients were started on treatment after written, informed consent.

The Ayurvedic Herbal Combination ( AHC ) comprises of eleven different herbs in different dosage strengths, based upon their respective potencies, reported anti-viral and immunomodulatory properties, and their traditional usage according to Ayurvedic principles of medicine 2 -4 .The constituents of AHC with their respective dosages are as follows:-Terminalia arjuna: 250 mg. ;Zinziber officinale: 250 mg. ;Phyllanthus niruri :1 gm ;Glycyrrhiza glabra:1gm. ;Withania somnifera:1gm. ;Eclipta alba: 250mg. ;Centella asiatica: 250mg. ;Boerhavia diffusa: 250mg. ;Emblica officinalis: 250mg. ;Tinospora cordifolia: 250mg. ;Rubia cordifolia: 250mg. This AHC was dispensed in a combined dose of 5 gms. t.i.d., to be taken with water after meals. Aqueous herbal extracts of all the medicines were used, in tablet form.

All patients were advised to eat a well-balanced, nutritious diet. Therapeutic counseling sessions were conducted regularly to help the patients achieve mind relaxation, to modify their risk behavior , and to increase adherence and compliance to therapy.

All patients were followed up at monthly intervals. Detailed clinical examination was done at each visit and significant findings were recorded. In addition, in affording and willing patients, investigations like CBC, Hb, Liver and Renal functions, X-Ray of chest, Western Blot, CD4 count and Viral Load were done wherever possible. Other investigations were done, if required, for Opportunistic Infections (O.I.).All O.I. were promptly and aggressively treated with modern medicines. A close watch was kept for adverse reactions of the drugs.

Therapeutic outcome was assessed by overall clinical examination, change in Karnofsky score (assessment for overall well-being of patients), change in weight, occurrence and response to O.I., and change in CD4 and Viral Load values. Maximum number of patients was in the age ranging from 20 - 39 years (80 %). Of the total number of 55 patients, 39 were male (71 % ) and 16 were female (29 %), with the male: female ratio being 2.4: 1. There were 7 couples who took treatment together.

Of the 55 patients, 5 patients died, 42 patients took treatment for varying periods and then stopped treatment, while 8 patients continued treatment till the end of the study period. The 5 patients who died were critically ill at the time of presentation, and died mostly within the first two months of starting Ayurvedic treatment. The cause of death varied ; 1 patient died from cirrhosis of the liver, 3 died of extensive Pulmonary Tuberculosis (multi-drug resistant) and 1 died of a combination of Pulmonary Tuberculosis and demyelination disease of the brain.

In the 50 patients who were alive till the time of their last follow-up , there was an average weight-gain of 2.3 kgs.(range = - 4 to + 7.5 kgs), usually within the first 3 months. In those patients who took continuous treatment for more than 3 months, the Karnofsky score increased from an average of 75.9 at the commencement of treatment to 87.4 at the last follow-up. Almost all the patients had 1-3 O.I. at the time of presentation. Other than Tuberculosis, all the O.I. cleared up rapidly within the first 2 months of treatment.

Long-term administration of Ayurvedic medicines (upto 30 months) did not seem to have any major adverse effects. In fact, in a few patients, the tests for liver and renal function appeared to normalize further, with treatment. Haemoglobin readings gradually improved in those patients taking regular, prolonged treatment.The most striking effect of the Ayurvedic medicines was on the Viral Load and CD4 counts. Because of financial constraints, only 15 patients (27 % ) agreed to do either the Viral Load or the CD4 count, or both. In most patients, there was a definite and steady decrease in the Viral Load, and an increase in the CD4 cell counts.

Antiretroviral medicines are the mainstay in the modern treatment of HIV/AIDS. However, a plethora of side-effects, development of resistance to drugs and escalating treatment costs are serious concerns. In the absence of a definite cure for HIV/AIDS, Ayurvedic medicines may provide a useful alternative for long-term management of patients, since these medicines are economical and devoid of serious side-effects. However, scientific research is necessary to determine efficacy of these medicines. This retrospective study is one such effort to assess long-term therapeutic effects of an Ayurvedic Herbal Combination in the management of HIV /AIDS.

In this study, 4 patients died within the first 2 months of commencing treatment. Onset of therapeutic effect is slow with Ayurvedic medicines, and these patients probably could not benefit from Ayurvedic treatment. This emphasizes the need to start treatment as early as possible in immuno-compromised patients. The causes of death indicate that Tuberculosis and CNS involvement are major killers in HIV patients. Multi-drug resistance to Tuberculosis is also a major concern.

16 patients ( 29% ) did not come back after just one ( 11% ) or two ( 18% ) visits. The reasons cited were, a complete inability to pay for treatment, or a search for a ‘better’ or a ‘guarenteed cure’. Fortunately, perceptions have changed in the last few years. Even illiterate patients from the lower socio-economic strata are no longer asking for a ‘guarantee’ or a ‘cure’. ‘Long-term management with minimum expenses’ is a mantra being readily accepted by the HIV positive patient of today.

All the patients who took medicines regularly, had a high-protein diet and kept themselves busy, improved very well and put on weight. Even 2 to 3 years after stopping Ayurvedic treatment, most of the patients are doing very well, some inspite of very low CD4 counts. This is probably one of the biggest long-term advantages of taking Ayurvedic medicines for HIV /AIDS. However, patients with socio-economic difficulties and a lot of psychological pressure who could not have access to regular treatment, started losing weight after initially improving with treatment. A comprehensive management of each patient thus needs to address several issues relevant to each individual patient.

This study also brought forth some interesting results. One patient who subsequently died, had severe demyelinating disease of the brain (as diagnosed in a major hospital), and had lost most of his motor control and sensory senses, since several months. After being given Ayurvedic treatment for about 1 ½ months he became alert, and could speak clearly, albeit temporarily, for 1 week. Another patient with Nephrotic syndrome resulting in long-standing generalized oedema (2 years ) had complete regression of the oedema after 2 months of Ayurvedic treatment without any other treatment. One HIV positive patient with suspected malignancy of lung in the right upper lobe was steadily losing weight. After starting Ayurvedic treatment, he started putting on weight. Another patient with history suggestive of HIV Encephalopathy was semi-conscious at presentation. He was passively fed on liquid diet and a combination of both modern drugs and Ayurvedic treatment. This patient be!

came ambulatory within 2 weeks, and after 2 months of treatment he was faring well, even with a CD4 count of just 6.The above 4 instances indicate that the Ayurvedic medicines may have multi-faceted properties and need further evaluation.

Thus,the retrospective study of 55 HIV positive adult patients treated with an Ayurvedic Herbal combination from April 1999 to November 2004 proved the Ayurvedic medicines to be highly effective as anti-viral and immuno-stimulant,and safe on long-term use. A nutritious diet, Ayurvedic baseline therapy, timely allopathic treatment of Opportunistic Infections and regular counseling support appears to be an ideal combination in the management of HIV/ AIDS patients.

References
1. UNAIDS. Global Summary of the AIDS Epidemic. Update December 2007.
2. Foundation for Integrative AIDS Research. Potential Anti- HIV Herbs. 15/9/2002.
3. Sharma P.V. Vegetable Drugs. Vol. II. IV Edition. Chaukhamba Publications.1978.
4. Dahanukar S A, Kulkarni R A, Rege N N. Pharmacology of Medicinal Plants and Natural Products. Indian Journal of Pharmacology, 2000; 32: S81 - S118.

About The Author
Dr. A. A. Mundewadi is Chief Ayurvedic Physician at Mundewadi Ayurvedic Clinic based at Thane, Maharashtra, India. He is available as an online Ayurvedic Consultant at http://www.ayurvedaphysician.com/ and can be contacted at info@ayurvedaphysician.com

Dr. A. A. Mundewadi, B.A.M.S., is a practicing Ayurvedic physician since the last 22 years. He is a graduate of R. A. Podar Medical (Ayurvedic ) College, Worli, Mumbai, India. During this period of 22 years, he has obtained considerable experience in the clinical treatment of a vast array of patients.

Ayurveda , basically means, a “ Science of Life”, and involves maintaining the health of healthy persons, and treating sick patients. Dr. Mundewadi has studied and experienced extensively all the principles of Ayurveda , involving a healthy life-style, diet regimes, body-cleansing through panch-karma procedures, and treatment with herbal and herbo-mineral compounds.

In addition to his background in Ayurveda, Dr. Mundewadi has also studied the therapeutic effects of Reiki( he is a 3rd degree Reiki Master), Acupuncture ( he has done a basic and an advanced course in Acupuncture), Hypnotherapy and Magnetotherapy. His current style of clinical practice is a culmination of his experience with all these different treatment modalities.

Dr. Mundewadi has been doing clinical research work since the last 9 years. He has published his findings of herbal treatment of HIV / AIDS in 55 patients in the Bombay Hospital Journal, Mumbai, India, July 2005 issue,which can be viewed at www.bhj.org/journal/2005_4703_july.html/original_aretrisoective_255.htm . He has also successfully completed a clinical trial of herbal extract medicines in Schizophrenia compared to modern anti-psychotics, in 200 patients( See www.clinicaltrials.gov/ct/show/NCT00483964 ). He has also conducted preliminary studies of Ayurvedic herbal extracts in the treatment of Bipolar Disorder, Vascular Dementia, Alzheimer’s Disease, Parkinson’s Disease, Attention Deficit Hyperactivity Disorder, Autism, Mental Retardation, and Tobacco and Alcohol Dependence. He also has a special interest in the herbal treatment of Age Related Macular Degeneration and different types of Cancer.

Copyright Clause: This article may be reproduced with full acknowledgement of the author's name and contact(url and E-mail) details.

2007/11/24

My Cure Theory for HIV - AIDs

By leo le [ 12/01/2006 ]

My Cure Theory

HIV has many different strands or forms making it almost impossible to find an efficient answer for vaccination. Over in other countries (Asia and Africa to name a few) where there is prostitution, scientists have discovered that prostitutes have become immune to the virus in a couple different ways. Scientists have discovered that the immune system of prostitutes has found a way to fight the virus. How could this be? HIV is being stopped in its tracks from becoming Aids. Is the virus, HIV fighting against different strands or forms of itself? Think about it. You have different strands of the virus, meaning several different partners with different types of strands of HIV. You have a prostitute with one type of strand (the control patient). The resultant different strands introduced to a control patient with one strand equals different outcomes. After years of research and billions of dollars in funding, ironically, sexually, prostitution has found a key to fighting Aids. There are no known cures for viruses or even for the common cold. But figuratively speaking why try so hard to fight an enemy, when you can use an enemy against themselves. With the discovery of different strands and forms of viruses, is there a possible way we can use a virus against itself? Bottom line is that sometimes finding a cure for something can seem almost impossible but fighting fire with fire can result in the ultimate answer. Keep in mind with every new idea or answer arises many questions for the long term outcome. Our answers to life may give us new hope but may also be our ultimate downfall. I wrote this just to get a professional medical research opinion. This virus has been around for ages and needs to be stopped like all other bad diseases and viruses. I just wanted to post my idea in good faith to help find a cure.

About the author:

Article written by Nghiep Khuu “Leo Le” on Sunday, December 18, 2005. Updated today 1/12/06.

Article Source: http://www.Free-Articles-Zone.com

2007/09/14

Herbal and Natural Aids Cure Hiv

Source : http://www.articlesbase.com/alternative-medicine-articles/herbal-and-natural-aids-cure-hiv-61434.html

Author: Drrao

The word HIV/AIDS is so threatening that it had created a fear in the mind of the people. This is a deadly disease where the people are knowingly or unknowingly getting addicted to it. Many innocent people are becoming victims to this disease.

The medications which are curable with no harm and side effects that is the dietary supplements. So ultimately you have chosen a right place for your medications which are tried, tested and the proven ones with no side effects and no harm.

When we see the stats of the chronic diseases like aids, cancer and others are increasing in number than decreasing. This happens due to these main things that are improper diet, lack of nutrition, breathing impure air, having junk foods, getting addicted to the bad habits and many more. The people are really not thinking of the healthy living they just want to lead the life of their wish. And this is the main reason why the man is getting affected with such chronic diseases.

More information meets: dr jack

HIV AIDS is an infectious disease which causes lots of death in the world wide. This is deadly disease where the person battles with the life and death. He fights for the survival and getting rid of the disease. But this fatal disease does not allow them to lead a life. It goes on killing the person with depression or any with other reasons.

What is HIV and AIDS?The word HIV stands for Human Immune Deficiency Virus and AIDS stands for Acquired Immune Deficiency Virus. The HIV is a viral that uses the nutrients and energy provided by the human cells to grow and reproduces to infect the human cells. AIDS is the next final stage of HIV which makes breakdowns the immune system of the human body and makes unable to fight against infections or the other illness. But sometimes it takes decade or two to turn out from HIV to AIDS if the person has started to undergo the medical care. The symptoms may not be seen for years together to some they may get it later also.

This disease can be seen even in man, woman or even children. According to the estimates of the United Nations HIV/ AIDS says that there are approximately 40 million of HIV/AIDS sufferers. But this is not getting an end at all. Day by day this disease is increasing in the people. They are getting affected with it in one or the other way. This disease has killed millions of people and have left millions of the children as orphans away from the love of parents. It has made its wide by conquering the place of the deadly diseases like malaria and tuberculosis. The wide spread of this disease in the world has made it to stand in the fourth position for the more death causes in the present generation. The transmission of this disease is as follows:

Unprotected sexual intercourse with the positive person either vaginal or anal.
Unprotected oral sex with the someone who has HIV.
Sharing needles and syringes with someone who has HIV without sterilizing it.
Infection during pregnancy.
Mother to child in the womb.
Breast feeding to the baby.
From a blood transfusion from positive person to healthy person.

How to prevent the disease from
Not sharing the needles and syringes which are used to inject drugs after used by a person. either he may be a positive or not.
Not to have sexual intercourse with many and if you have
then their is an urge to use the protection condom during it.

Not to have the sexual relationship with the person who has been positive.Have a test over the blood before its transfusionUse the sterilized or new needlesEducate yourself and try to spread about this to the people who are vulnerable about it

The utmost and bottom line is that you should treat someone with HIV or AIDS the same as anyone else. In fact, they need your friendship and support more than ever. Just think how you would feel in their place. Now a man can survive for years together after getting HIV infection. This can happen when the man starts to have medical care before they begin to get sick. Knowing that you are HIV positive you will take precautions to prevent others being affected from it. But yet the HIV is scary stuff as it has no cure, no medicine, and no vaccine to prevent AIDS. But we have to be thankfully that the virus doesn't easily enter the body from person to person. And Aids Is surely cure by herbal and natural products these are the effective and safe treatment for HIV aids

About the Author:
Dr Jack is a Conventionally Trained Western Medical Doctor from India and fellow of American Academy of Pediatrics (AAP). He is also trained in traditional supplements since the age of 5 years to practice complimentary alternate supplements.For more information contact: dr jack

2007/08/25

Could green tea prevent HIV?

source : http://www.accessmylibrary.com/

Green tea: fact or fiction

Publication: HIV Treatment: ALERTS!
Publication Date: 06/01/2007
Author: Nance, Christina L.

The Center for AIDS: Hope & Remembrance Project

Scientists have discovered that a substance in green tea prevents HIV from attaching to our immune system cells by getting there first. According to researchers from Baylor College of Medicine in Houston and the University of Sheffield in the England, in a report that appears in the Journal of Allergy and Clinical Immunology (1), a compound in green tea called catechin, (also known as epigallocatechin gallate [EGCG] or flavonoid) blocks the ability of HIV to enter and destroy the immune system.

The health effects of brewed green tea are attributed to numerous chemical substances that make up 30% of dried leaf extract. Of these, EGCG is the most active. Similar substances in other plants have been found to be less plentiful and have fewer medicinal properties. EGCG binds well to many molecules and affects a variety of enzyme. It is this specific aspect of green tea that researchers think is responsible for its many reported health benefits.

Animal studies have shown that drinking green tea is associated with a lower rate of cancer in humans. The major component of green tea, EGCG, is thought to be the most potent cancer-preventive component of the catechins. This protective effect of green tea has been evaluated in pancreatic, colon, rectal, skin, breast, prostate, liver, and lung cancel: Recently EGCG has emerged as a potential candidate in the fight against AIDS. Investigators have found that its antiviral effects can be targeted at HIV infection. However, this does not mean you should start drinking gallons of green tea every day. But, there is some encouraging news.

HIV infection results in damage to the immune system when the gpl20 glycoprotein (a protein that has sugar molecules attached to it) latches onto the T cell. Even though gpl20 produces antibodies that help light against the virus, HIV manages to escape, leading to infection. Ever since the discovery of the virus as the cause of AIDS, there has been an intense effort to develop methods to slow down or prevent HIV infection. Until now, scientists have spent much of their time trying to find ways to build up the immune system to prevent HIV from attaching itself to the T cells. Christina L. Nance, PhD, and William T. Shearer, MD, PhD, of Baylor College of Medicine and Texas Children's Hospital, and Mike R Williamson, PhD, of the University of Sheffield, began looking at ways to get high enough levels of EGCG into the body for it to be able to protect the body against HIV. They paired the T cell with gpl20, then paired the T cell with EGCG. By studying the physical structure of the T cell, they realized that EGCG hooks onto the same exact pocket on the T cell as gp 120. This ability to block gp 120 is its most important feature since it prevents the initial encounter of HIV with T cells.

If EGCG proves to have value as an HIV treatment, it probably will not be used alone. It would be part of a combination of drugs. The researchers do not recommend that people drink large quantities of green tea with the expectation that it will prevent infection with HIV. These studies are designed to determine whether a drug derived from green tea would have that effect. The next phase of the research will be testing EGCGin humans.

(1) Journal of Allergy and Clinical Immunology 118(6): 1369-74, Dec 2006. Christina L. Nance, PhD, is Instructor and Research Laboratory Supervisor at Baylor College of Medicine, Department of Allergy/Immunology, Texas Children's Hospital.

-----------------------------------------------------------------
My comment : It's such a good news that brings much hope for many HIV patients, but I doubt can it works in human. There are also just a few research,so it dosen't mean that patients should drink a gallon of green tea. Instead of drinking green tea as water, they should beware of their health, exercise to be healthy, take off drugs as the practitioner prescribes ontime (Important: don't forget it) and just relax their mind. All of these are much more important to have a good quality of life.

2007/08/24

FUZEON: avoiding injection-site reactions

source : http://findarticles.com

AIDS Treatment News, Nov-Dec, 2006

On January 31 the FDA announced that the FUZEON (enfuvirtide) package insert had been changed to include precautions to avoid injection-site reactions, either using a needle, or the Biojector(r) 2000 needlefree injection system. For example, here is one place where changes were made (this is from the new version):

"Patients and caregivers should be instructed on the preferred anatomical sites for administration (upper arm, abdomen, anterior thigh). FUZEON should not be injected near any anatomical areas where large nerves course close to the skin, such as near the elbow, knee, groin or the inferior of medial sections of the buttocks, skin abnormalities, including directly over a blood vessel, into moles, scar tissue, bruises, of near the navel, surgical scars, tattoos or bum sites."

2007/08/07

Ten Tips on Injecting Fuzeon

Source : http://www.thebody.com/fuzeon/tips.html

Fuzeon -- A Review of the First Entry Inhibitor

By Karlissa Foy, R.N., B.S.N. and Calvin Cohen, M.D., M.S.
2003

1.Add the Fuzeon powder to the sterile water solution provided. To ensure that the powder dissolves completely into the solution, roll the vial slowly at an angle. It should look like water when it has completely reconstituted.

2.If it's more convenient, while preparing one dose, you can always prepare the "next" dose. This means you can reconstitute two vials at once, using one immediately and refrigerating the second vial (vials can be prepared at most up to 24 hours in advance). However, always make sure the vial is at room temperature before you use it to inject. Some people say that after refrigerating the Fuzeon, it is not only easier to inject it, but there are fewer skin reactions at the spot where they inject.

3.Try a hot bath or shower just before injecting. This may make your skin more supple and easier to inject into.

4.Don't be afraid to try other needles besides those supplied to you by the pharmacist. Ask your doctor about insulin or tuberculin syringes. These have slightly smaller needles (in width) that do not automatically retract. Some people find these needles easier to work with.

5.Be sure to change the places where you inject, so no one spot becomes too tender or develops too severe a reaction. Don't worry if you don't have enough fat under your skin. There is no clear evidence that people with less fat have worse skin reactions.

6.You can inject in your "love-handles" -- some patients have noted that they have fewer skin reactions to the injections in areas where there is more fat.

7.Pay attention to the angle of the needle when injecting. If you don't have a lot of fat on your body, pull your skin up a little and make sure you're injecting only into your skin. If you have enough fat under your skin it will be easier. The idea is to avoid muscle injections, which can be painful.

8.Use a clothespin or clip to pinch the skin in areas of injection that you find hard to reach.

9.Vigorously massage the area where you are going to inject the Fuzeon for 3-5 minutes both before and after injection, with the emphasis on "vigorous." Use a vibrator as a tool for vigorous massage!

10.Apply a warm (not hot) towel to the site of injection immediately following injection.

For more information on injecting Fuzeon, click here.

Glossary http://www.thebody.com/fuzeon/glossary.html

Conclusion: Fuzeon's Role in Treatment

Source : http://www.thebody.com/fuzeon/conclusion.html

Fuzeon -- A Review of the First Entry Inhibitor

By Calvin Cohen, M.D., M.S.
2003

Remember that Fuzeon is, ultimately, not a whole lot different from the HIV medications that came before it. Although it works differently than previously approved HIV medications, and has the novelty and challenge of being injected -- requiring a new set of skills by providers and the people using it -- it ultimately is just another HIV medication.

The suppression of HIV provided by Fuzeon in combination with other mediations can last a long time and help your immune system rebuild itself. This can help your health improve over time.

However, Fuzeon has some of the same vulnerabilities and challenges shared by all medications. Although HIV can develop resistance to it, it works best and lasts longest when it is combined with at least one other working medication, preferably two other potent medications. It can provide substantial HIV suppression when used within an already-working regimen and can more than double the rates of suppression when incorporated into the regimens of people facing resistance to the other drug classes.

Fuzeon is a vital drug to understand as we confront the formidable task of providing effective treatment for the many people facing resistance to prior regimens. It is the only drug from a new class that will be available during the next few years. When used correctly, it has provided real and long-lasting HIV control, and has been a critically important contribution to the fight against HIV.

Fuzeon's Side Effects

Source : http://www.thebody.com/fuzeon/side_effects.html

Fuzeon -- A Review of the First Entry Inhibitor

By Calvin Cohen, M.D., M.S.
2003

What is clear from the big clinical studies on Fuzeon is that most HIV treatment-experienced people felt physically better once Fuzeon was included in their regimen. Many of the most common side effects reported with other HIV medications -- such as nausea or diarrhea -- were actually less common in people receiving Fuzeon. This is partly because Fuzeon does not appear to cause these problems, and partly because some of these toxicities were potentially caused by HIV and with HIV under better control, the success of the treatment made these symptoms less common.

Fuzeon's only common side effect is a skin reaction around the area where the drug is injected. While most everyone who takes Fuzeon notices some irritation at the injection site, only about 4 percent of people found this uncomfortable enough to stop the drug within a year.
In clinical studies, about half the people taking Fuzeon rated these reactions as "mild" -- which means that they were relatively small, lasted only a day or so and did not require any treatment for discomfort. However, about 25 percent of patients did report having "moderate" reactions. This may mean that the reactions were a bit larger, lasted a bit longer or had made their skin more tender. But again, these side effects were manageable even after people took Fuzeon for one year.

Researchers are trying to assess what techniques might assist people who are dealing with these reactions, in terms of how to inject differently or what to do after receiving an injection. However, a few observations have been shared by many nurses involved in these studies that may be of help:

Inject only superficially in the skin. Avoid going deeper -- injections anywhere near the muscle are more painful.

Avoid injecting near a spot that is already tender, since a second injection might increase that discomfort. It is important to inject in different places.

Other observations are being gathered and will be shared by researchers as they are verified over time. See our ten tips on injecting Fuzeon for more advice.

Who Fuzeon Works Best For

Source : http://www.thebody.com/fuzeon/patients.html
Fuzeon -- A Review of the First Entry Inhibitor

By Calvin Cohen, M.D., M.S.
2003

Is there one type of patient who would most benefit from Fuzeon? After analyzing the TORO studies, researchers discovered four factors that could statistically predict whether a person's viral load will drop below 400 copies after 24 weeks of taking an optimized background regimen with Fuzeon.

People were more likely to be successful on this regimen if, at the time they started it:
Their CD4 count was more than 100.
Their viral load was less than 100,000.
They had already used 10 or fewer HIV medications.
They began Fuzeon treatment with at least two other HIV medications that still worked against HIV, as judged by a resistance test.

The TORO studies showed that Fuzeon tends to work better for people with less-advanced HIV infection -- a conclusion that is similar to most of the findings for all other HIV medications currently in use. However, what is notable about these results is that they reinforce important issues with regard to the timing of using this drug.

Because Fuzeon was developed for people who had low CD4 counts and who were already resistant to NRTIs, NNRTIs and PIs, doctors might choose to "save" Fuzeon for this late stage of treatment. Clearly, for those with low CD4 counts and few other options, Fuzeon does represent an important breakthrough option, because it might provide at least partial suppression and increase a person's CD4 count.

However, what is clear from these analyses is that there are people with less-advanced disease who may also benefit from the inclusion of Fuzeon in their regimen. For example, someone who has already developed resistance to one NRTI/NNRTI-based regimen and one PI-based regimen -- and who is about to start on a third regimen -- might also benefit from including Fuzeon as the "anchor" in his or her next regimen. The timing of using Fuzeon is among the most complex discussions that doctors must have with patients when dealing with resistance and treatment options.

In summary: While there are many details that must be considered when deciding on your next regimen and predicting its success, it is at least important, based on the data currently available, to consider adding Fuzeon to your regimen well before you develop complete resistance to virtually all other medications. Waiting until that happens will only limit Fuzeon's benefit.

What We Know About Fuzeon

Source : http://www.thebody.com/fuzeon/efficacy.html

Fuzeon -- A Review of the First Entry Inhibitor

By Calvin Cohen, M.D., M.S.
2003

Efficacy: Just How Good Is This Drug?
In initial studies of Fuzeon, it was given to people alone (not as part of a regimen with other drugs) for about one month. This is the standard way to evaluate how powerful an impact a new drug will have on the ability of HIV to reproduce itself. From these studies, we learned that Fuzeon is about as powerful as most of the other potent HIV medications. We saw that an average person's viral load would decline by about 1.5 logs, or about 96 percent, when Fuzeon was used alone as a single drug.

Translating this into viral load: If someone had a viral load of 10,000, a decline of 96 percent would result in a viral load of just under 400. However, since we know that HIV can develop resistance to Fuzeon -- just like HIV does with any other drug when more complete suppression of HIV is not established -- the largest clinical studies on Fuzeon were all conducted with a combination of medications that included Fuzeon, in order to give everyone the best chance possible of suppressing HIV.

Clinical Trial Results
The big clinical studies conducted with Fuzeon were called the "TORO" studies. They enrolled about 1,000 people on several continents. To be eligible, people had to be "treatment experienced" -- that is, they had to have taken all three of the other classes of HIV medications: NRTIs, NNRTIs and PIs. The researchers made this group the target population primarily because they are most in need of a new class of HIV medications -- they are resistant to all three classes of HIV medications and had run out of options for finding a regimen that would durably suppress HIV replication, so they had the most to gain if Fuzeon worked.

The studies were designed to closely resemble what doctors would normally do in their clinical practice, in order to make these trials as easy and as relevant as possible. Patients who were eligible were randomly chosen to receive either the best HIV treatment combination their physician could put together using three to five HIV medications (called the "optimized background"), or this same "optimized background" regimen with Fuzeon added.

To create the optimized background regimen, doctors were allowed to use a combination of three to five of the approved HIV medications that were available at the time. People were given a resistance test before they were accepted into the study so doctors could select the best drugs for them. In addition, doctors had a complete treatment history for each person to help them more accurately choose drugs that would be as well tolerated as possible.

The treatment-experienced patients enrolling in this study had, on average, low CD4 counts and high viral loads. The average CD4 count in these studies was about 90 cells/mm3, and the average viral load was just over 100,000 copies/mL. Nobody took a placebo -- everyone in the study received either the standard "optimized background" regimen, or an optimized background regimen plus Fuzeon.

There was a humane aspect to the design of these studies. If in the first year a person's regimen failed to suppress HIV while on the background arm, he or she was permitted to "cross over" and receive Fuzeon plus a new background regimen.

The results -- which were measured after 24 weeks and again after 48 weeks -- demonstrated the importance of adding Fuzeon to a background regimen. Overall, by week 24, those receiving Fuzeon plus an optimized background regimen had approximately doubled their chances of achieving viral suppression (to either below 400 copies or even down to below 50 copies). This additional rate of suppression occurred since, on average, Fuzeon made the optimized background regimen almost 90 percent more effective. This means that these people had a nearly 90 percent lower viral load than people who were only taking an optimized background regimen.

Of note, those on just the optimized background had, on average, a total viral load drop of only 0.7 log, which is about the same viral load drop that we see when starting a treatment-naive patient on just AZT (zidovudine, Retrovir) alone. This study documented just how much resistance there was among treatment-experienced people in this study.

In summary, analyses of this study demonstrated the success of Fuzeon in people who are already resistant to many other HIV medications. For example, when researchers used one definition of success -- i.e., a viral load that is at least 90 percent lower than at the start of the study -- about twice as many people were able to achieve treatment success after 24 weeks just by adding Fuzeon to their regimen. After 48 weeks, 37 percent of the people taking Fuzeon still had viral load reductions of at least 90 percent, while only 17 percent of people in the optimized background arm were able to maintain such a decline in their viral load.

There are two types of viral load tests: one that can't detect viral loads below 400, and a more stringent one (which is usually used in the U.S.) that can't detect viral loads below 50. Regardless of which measure was used in this study, over twice as many people taking Fuzeon with their regimen had "undetectable" viral loads as people who were not taking Fuzeon. At week 48, for instance, 30 percent of people on Fuzeon had viral loads less than 400 copies, compared to only 12 percent of people on an optimized background regimen alone.
Using the more stringent goal -- reaching a viral load of less than 50 -- 18 percent of people on the optimized background plus Fuzeon, versus 8 percent on only the optimized background, had an "undetectable" viral load to this degree.

Of note, a similar percentage of people with a viral load of less than 400 and less than 50 copies was noted at weeks 24 and 48. This reinforces the idea that lowering viral load to these levels is one important way to achieve a durable degree of viral suppression. As a result of this improvement in people whose viral load was suppressed, there was a corresponding larger increase in CD4 counts when the study reached week 48 in those receiving Fuzeon plus an optimized background (91 cells/mm3 increase) versus those people only on an optimized background (45 cells/mm3).

Resistance Still a Danger With Fuzeon
As with every HIV medication, resistance to Fuzeon can develop. Early studies in which only Fuzeon was used to fight HIV clearly established this. This resistance is made apparent in the form of "genotype mutations," although there are few if any commercial tests that can do such testing now.

What remains less clear so far is how powerful Fuzeon might be even after resistance develops. Is it like other HIV medications, such as 3TC, where HIV can still be partially suppressed even if there is resistance? While research is ongoing to understand this more fully, the research so far suggests that it's possible. Regardless, with Fuzeon (as with any other HIV medication), it is important to attempt to establish robust suppression -- preferably pushing a viral load to less than 50 copies, or at least less than 400 copies.

How Does Fuzeon Work?

Source : http://www.thebody.com/fuzeon/how_work.html

Fuzeon -- A Review of the First Entry Inhibitor

By Calvin Cohen, M.D., M.S.
2003

As mentioned in the last section, HIV inserts a glycoprotein into the CD4 cell wall, and that protein then acts like a zipper to bring HIV directly into contact with the CD4 cell. Fuzeon is like a piece of clothing that gets stuck in the zipper: When Fuzeon attaches to a specific part of the glycoprotein which HIV has inserted into a CD4 cell wall, the glycoprotein can no longer zip itself together, which completely halts the process of HIV fusing with the CD4 cell. Once this process is stopped, as long as Fuzeon remains effective, HIV cannot progress in your body.

That is why entry inhibitors are also known as fusion inhibitors -- they stop the fusion of HIV to a CD4 cell.

Because fusion is completely unrelated to all the other steps in HIV's life cycle that current HIV medications are designed to block, no cross resistance exists between the other classes of HIV medications and Fuzeon. This means that, essentially, everyone with HIV is susceptible to fusion inhibition with Fuzeon. This new class, then, can provide an important "anchor" in a new treatment combination for those who are switching regimens. Therefore, Fuzeon provides a new opportunity to reestablish control of HIV infection.

Fuzeon has several unique features. One is that, unlike all the other HIV medications, Fuzeon must be taken by self-injection. What this means is that to get Fuzeon into your bloodstream, you would be given a small syringe for a simple injection under the skin, similar to how people take insulin. Fuzeon is given as an injection for a similar reason to why insulin is an injection: Fuzeon is a type of molecule that, if taken orally as a pill, will be destroyed in the process of digestion.

Although at first you might feel uncomfortable using a syringe, in most every doctor's office there is someone -- usually a nurse -- who can teach you how to inject this medication by yourself at home.

Entry Inhibitors: A New Class of HIV Medications

Source : http://www.thebody.com/fuzeon/entry_inhibitors.html

Fuzeon -- A Review of the First Entry Inhibitor

By Calvin Cohen, M.D., M.S.
2003

How Does HIV Enter Our Cells?
To damage the immune system, HIV must first get inside your CD4 cells, which are responsible for fighting off diseases inside your body. After HIV enters your CD4 cells, it uses several enzymes to turn the cells into factories that produce more HIV. Two of the key enzymes that HIV uses once it gets inside a CD4 cell are the reverse transcriptase and protease enzymes, which have been the focus of the first three available classes of HIV medications.
Researchers have figured out several of the critical steps that HIV follows to get inside CD4 cells. This has been broken down into a few stages. Here's a play-by-play look at what happens:
First, HIV attaches to a CD4 receptor.

Then HIV attaches to a "co-receptor."

After this dual attachment (to CD4 and then to a co-receptor), HIV inserts a harpoon-like anchor called a glycoprotein into the CD4 cell wall.
Then HIV "zips" together the two ends of this glycoprotein (one end is in the CD4 cell; the other end is still attached to the virus). This action allows HIV to literally pull itself close enough to the CD4 cell wall so it can actually fuse with the CD4 cell.

To complete this step of connection (or fusion), an opening is created in the CD4 cell, and -- through a process scientists still do not completely understand -- HIV inserts its viral RNA into the CD4 cell. This allows HIV to begin the process of completely taking over the CD4 cell.
The goal of Fuzeon, the first entry inhibitor to be approved in the U.S., is to prevent HIV from entering CD4 cells by stopping it from "zipping" together the two ends of the glycoprotein.

Introduction: Why Do We Need a New Class of HIV Medications?

Source : http://www.thebody.com/fuzeon/intro.html

Fuzeon -- A Review of the First Entry Inhibitor

By Calvin Cohen, M.D., M.S.
2003

Reason #1: Resistance to Current Drugs
Treating HIV infection involves many challenges, including occasionally troublesome side effects and the difficulty of taking once- or twice-daily medications for a long period of time.
But one of the most difficult challenges is what to do when a medication no longer has any effect on HIV. When this happens, we say that HIV is "resistant" to a medication. This means that the amount of HIV in your body is able to grow despite the presence of that medication in your body.

Once resistance develops, it's not the initial return of HIV reproducing inside your body that causes a problem for the immune system; after all, HIV usually doesn't return in very high numbers. The problem is that once HIV is given even a little leeway to grow, it tends to begin mutating -- that is changing its genetic structure -- more and more. Each mutation helps HIV thrive, and as it does, it can cause additional immune damage.
And, of course, the more your immune system is damaged, the more vulnerable you are to a host of other, often dangerous, infections. Researchers continue to look for ways in which you can maintain a healthy immune system despite the low-level presence of HIV. In addition, researchers are always looking for combinations of HIV medications that can contain HIV for long periods of time despite this low-level presence.

One clear goal of HIV treatment is to avoid resistance and to "suppress" HIV, or stop HIV from reproducing itself. When HIV is fully suppressed, it is "undetectable" in your blood, meaning that although HIV is still present in your blood, we cannot see it with the viral load tests currently available. (It should be noted, however, that viral load tests do not measure the presence of HIV in body tissues such as the lymph nodes or the brain, just the presence of HIV in the blood.)

Once HIV is "undetectable," resistance usually does not occur and treatment will be far more reliable, long-lasting and successful.

Reason #2: Cross Resistance
Another challenge in HIV treatment is the occurrence of "cross resistance." Cross resistance occurs when a mutation in HIV allows HIV to "ignore" or resist the effect of more than one medication -- including a medication that someone may never have taken. So, despite the fact that we have about 20 different FDA-approved HIV medications, if your HIV becomes resistant to almost any of these medications, there will be some degree of cross resistance to other medications -- even though you have not yet used them.

Cross resistance is particularly a concern if, when you were first infected with HIV, you were infected with a strain of HIV that already had some resistance mutations. When this is the case, even before your treatment begins, there may be fewer combinations of HIV medications that will work reliably.

It is important to understand that cross resistance occurs within a specific "class" of antivirals. Researchers categorize each HIV medication within a class based on similarities in the way each medication stops the growth of HIV in the body. For the past several years, HIV treatment has been based on a combination of at least three different medications from one or more of three classes: nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs).

So, for example, if you develop resistance to one NNRTI such as nevirapine (Viramune), you're almost guaranteed to have cross resistance with another NNRTI such as efavirenz (Sustiva, Stocrin).

Cross resistance, however, is much more likely to happen with NNRTIs than with NRTIs or PIs. With NRTIs and PIs, another drug within the same class can still be used if you develop resistance to the first one you try. For example, if you are resistant to 3TC (lamivudine, Epivir), which is an NRTI, you will be cross resistant primarily to FTC (emtricitabine, Emtriva), but cross resistant to a much lesser extent with other NRTIs, such as tenofovir (Viread) or d4T (stavudine, Zerit).

It should be noted that even if there is not complete cross resistance between two drugs, it is possible for the mutations that made HIV resistant to one drug give HIV a "head start" in creating additional mutations that can eventually make HIV resistant to other drugs.

These problems explain why so many people with HIV now have treatment-resistant strains of HIV. Many HIV-positive people have a hard time finding treatment combinations that will reliably suppress HIV for years and not cause many side effects. Therefore, if their HIV is not completely suppressed, they develop strains of HIV that have become at least partially resistant to several available medications. Furthermore, there are now many people who have at least some degree of resistance to all three classes of antivirals used in initial therapy.

Fortunately, cross resistance occurs only within a class of drugs, not between classes. In other words, if you've become resistant to NNRTIs, you're still probably going to be fully susceptible to NRTIs and PIs (i.e., your HIV will remain vulnerable and able to be attacked by those classes of drugs). And when HIV is fully susceptible to enough new drugs, it can be fully suppressed.
For several years now, it has been understood that when you switch from one treatment combination to another after resistance has developed, choosing an "anchor" drug from a new class of medications is among the best ways to reliably reestablish HIV suppression. This is particularly true if most of the drugs available are less than fully potent because you have some degree of cross resistance.

The newest class of HIV drugs is the entry inhibitors, also known as fusion inhibitors. The first approved medication in this class is Fuzeon (enfuvirtide, also known as ENF or T-20). This breakthrough HIV medication offers an important option for people dealing with resistance.

Changing Antiretroviral Therapy: Why, When, and How

Source : http://hivinsite.ucsf.edu/InSite?page=kb-03-02-06
(See Reference and Table 1-3)

HIV InSite Knowledge Base Chapter
June 2006

Timothy Wilkin, MD, MPH, Weill Medical College of Cornell University
Marshall Glesby, MD, PhD, Weill Medical College of Cornell University
Roy M. Gulick, MD, MPH, Weill Medical College of Cornell University


Introduction

Once antiretroviral therapy (ART) is initiated, patients generally remain on medications indefinitely. A change in the ART regimen is often necessary because of both acute and chronic toxicities, concomitant clinical conditions, and development of virologic failure. The approach to patients who need to change ART will differ depending on several issues, including the reason for change, the amount of previous ART experience, and the available treatment options. For example, when patients develop an adverse effect to a drug during their first ART regimen, effective treatment may be easily accomplished by substituting another agent for the offending drug in the regimen. At the opposite end of the spectrum are patients with advanced HIV disease who have experienced toxicities, virologic failure, and drug resistance during multiple past treatment regimens and thus require a new treatment regimen. This chapter reviews these circumstances and provides clinical evidence and strategies for changing therapy.


Acute Toxicities

Toxicities from ART are common and may necessitate changes in medications (Table 1). These toxicities are typically not life threatening but can affect quality of life and negatively affect patients' willingness to adhere to their regimens. In fact, several cohort studies have suggested that toxic effects are a more common reason for changing ART than are virologic failures.(1-4) A review of published cohort studies that examined modification of initial ART regimens found that antiretroviral intolerance and toxicity were the most common reasons for changing therapy in 8 of 11 studies.(4) Gastrointestinal disturbance such as nausea, vomiting, and diarrhea was the most frequently cited toxicity leading to a change in an initial ART regimen, and this has been confirmed in a separate cohort study.(3) Most of the modifications due to intolerance in these studies occurred within 3 months of starting ART.(4) The large majority of the patients in these cohort studies were taking protease inhibitor-based regimens.

Investigators monitoring an Italian cohort of HIV-infected patients examined the outcomes of patients whose first ART regimens were based on nonnucleoside reverse transcriptase inhibitors (NNRTIs).(5) They found that clinical drug toxicity, which occurred in 18% of patients starting a nevirapine-based regimen and in 10% of patients starting an efavirenz-based regimen, was the most common reason for changing an initial ART regimen. In contrast to gastrointestinal disturbance with protease inhibitor-based regimens, hypersensitivity (eg, rash and hepatitis) was the most common reason for discontinuing a nevirapine-based regimen (12%), and central nervous system toxicity was the most common reason for discontinuing an efavirenz-based regimen (5%). In addition to the toxicities mentioned above, rash, headache, fatigue, and abnormalities in hematologic and liver function tests are common toxic effects leading to a change in ART.(3) In some resource-constrained settings, where ART regimens usually consist of an NNRTI (typically nevirapine) in combination with either zidovudine or stavudine plus a second nucleoside analogue, high rates of acute toxicities necessitating antiretroviral changes have been reported (6-8) These adverse effects include rash, hepatotoxicity, and anemia.

No absolute guidelines exist for determining when to change regimens if these toxicities occur. Given that many patients improve within a few weeks of starting ART, providers often attempt to control adverse effects with short-term palliative medicine (eg, loperamide for diarrhea and prochlorperazine or metoclopramide for nausea). Efavirenz-associated central nervous system toxicity often subsides within a few weeks after starting the medication (9) and is usually managed by reassuring the patient. In the case of acute toxicity attributable to a specific antiretroviral drug, same-class substitution of a drug with a differing toxicity profile is accepted clinical practice, based largely on anecdotal experience and descriptive data from clinical trials (eg, abacavir or tenofovir for zidovudine-related gastrointestinal intolerance). The decision to change antiretroviral medications is based on consideration of the severity of symptoms, efficacy of palliative medications, options for substitution, and risks associated with those options. The occurrence of adverse effects has been associated with reduced adherence,(10) and providers generally should offer a change in medications for patients who report diminished adherence due to toxicity. Modification of ART because of toxicity in patients who are starting an initial ART regimen does not seem to be associated with subsequent virologic failure.(11,12)


Chronic Toxicities

Certain toxicities emerge months to years after the initiation of antiretroviral medications. These include neuropathy, changes in body composition (commonly termed lipodystrophy), and metabolic toxicities (eg, dyslipidemia and insulin resistance) that are associated with an increased risk of cardiovascular events. Researchers have shown great interest in the strategy of changing antiretrovirals to manage these chronic toxicities. The presumed multifactorial etiology of such complications makes their study a challenge because >1 drug or class of drugs in a regimen may contribute pathogenetically to the toxicity. Nonetheless, investigators have addressed chronic toxicities by substituting drugs that have been linked epidemiologically to specific adverse effects.


Lipoatrophy

Lipoatrophy (eg, loss of subcutaneous fat in the face, extremities, and buttocks) is a component of lipodystrophy. Thymidine analogue use has been associated with lipoatrophy, and, in particular, stavudine use has been identified as a risk factor in several studies.(13,14) Although fat loss was once thought to be irreversible, small proof-of-concept studies have suggested that substituting zidovudine or abacavir for stavudine was an approach worthy of further examination.(15,16) In a landmark study, subjects with lipoatrophy were randomized to continue stavudine or zidovudine or to switch the thymidine analogue to abacavir. Those who switched had statistically significant increases in both subcutaneous abdominal tissue volumes by computed tomography and peripheral fat mass by dual-energy X-ray absorptiometry (DEXA) scanning at 24 weeks of follow-up.(17) Although these short-term changes were not clinically significant, further follow-up to 2 years demonstrated continued improvements in lipoatrophy.(18) Other studies have demonstrated improvements in lipoatrophy after substituting abacavir,(19,20) tenofovir,(20) or zidovudine (19) in place of stavudine, suggesting that this approach may be reasonable to consider if a patient's treatment history permits safe substitution. A patient with a history of abacavir hypersensitivity or documented resistance to abacavir would not be an appropriate candidate for this switch. Similarly, a history of single or dual nucleoside analogue therapy is associated with an increased risk of virologic failure after changing to abacavir, probably because of preexisting nucleoside resistance mutations, and precludes such a switch.(21)

Observational data have suggested that protease inhibitors may act synergistically with nucleoside analogues in the development of lipoatrophy.(22) Several small, randomized controlled studies in which a protease inhibitor was switched to an alternative agent, however, have not shown objective improvements in lipoatrophy.(22,23,24) For example, among 77 subjects randomized either to switch from a protease inhibitor to nevirapine or efavirenz or to continue the protease inhibitor, the 58 subjects with lipodystrophy at baseline showed no changes in body composition by DEXA or anthropometric measurements after 1 year of follow-up.(22) Contrasting results came from a subgroup analysis of a larger trial in which 8 subjects taking a regimen containing zidovudine and a protease inhibitor switched their protease inhibitor for abacavir. On average, these subjects gained small amounts of leg fat over 48 weeks, as assessed by DEXA, compared with 7 control subjects who remained on a zidovudine-based regimen that included a protease inhibitor.(25) Taken together, these data suggest that substituting another agent for a protease inhibitor is not likely to have a clinically significant impact on lipoatrophy, at least in the short term.


Central Fat Accumulation

Because increased truncal (visceral) fat has been linked epidemiologically to protease inhibitor use, the effect on truncal fat of switching to regimens that do not contain a protease inhibitor has been explored in several small studies, most of which have lacked a control group and objective end points.(26-28) In 1 randomized study, subjects with increased visceral abdominal tissue volume at baseline had greater reductions after switching from a protease inhibitor-containing regimen to abacavir, nevirapine, adefovir, and hydroxyurea compared with controls who stayed on protease inhibitor-containing regimens.(29) Lipoatrophy, however, worsened in those randomized to the change in regimens. In a metabolic substudy of a large randomized trial, no significant improvement was found in body composition abnormalities 24 months after patients switched from a protease inhibitor to abacavir, nevirapine, or efavirenz.(24) Overall, the approach of switching from protease inhibitors has not proven successful and cannot be recommended as a strategy for addressing increased truncal fat. Specific therapies for this condition are an active area of research.


Dyslipidemia

Hypertriglyceridemia and hypercholesterolemia have been clearly associated with the use of specific protease inhibitors and may occur within weeks after initiation. These toxicities have been managed successfully by switching within the protease inhibitor class or by switching to drugs from other antiretroviral classes. As an example of the first approach, replacing ritonavir with nelfinavir or nelfinavir plus saquinavir improved lipid profiles in a small, randomized study.(30) Similarly, substituting atazanavir for a protease inhibitor improved lipid profiles in uncontrolled studies (31,32) and in a randomized comparison with lopinavir-ritonavir.(33) The effect of substitution of a protease inhibitor with the combination of atazanavir and low-dose ritonavir is less clear; in 1 randomized study, atazanavir-ritonavir appeared to affect total cholesterol and triglycerides favorably, whereas lopinavir-ritonavir appeared to worsen these parameters.(34) Several studies have examined the approach of switching a protease inhibitor to an NNRTI or abacavir. These studies are reviewed in detail elsewhere.(35) In general, substitution of nevirapine (24,36) or abacavir (21,24,37) has had favorable effects on triglycerides and often on total cholesterol, whereas substitution of efavirenz has yielded mixed results.(27,36,38). However, in a randomized study, triglyceride levels decreased in the first 12 months after substitution of efavirenz, nevirapine, or abacavir for a protease inhibitor, but returned to baseline by 24 months.(24) Changing to efavirenz or nevirapine may increase high-density lipoprotein cholesterol,(35,36) but may have variable effects on low-density lipoprotein (LDL) cholesterol.(24,36)

Nucleoside analogues also may contribute to dyslipidemia in HIV-infected patients. Stavudine has been associated with greater adverse lipid effects in 2 randomized, controlled studies when compared with zidovudine or tenofovir, in conjunction with lamivudine and efavirenz or nelfinavir.(39,40) Several studies have suggested that substituting tenofovir for stavudine may improve total cholesterol and LDL cholesterol; the effect on triglyceride levels is less clear.(20,41)


Insulin Resistance/Diabetes Mellitus

The effect of drug substitution has been characterized less well for insulin resistance than for dyslipidemia. Whereas indinavir clearly causes decreased insulin sensitivity when administered to healthy, HIV-uninfected volunteers,(42,43) the relative effects of other protease inhibitors have not been clearly discerned in vivo. In vitro data concerning insulin resistance (44) and diabetes mellitus associated with protease inhibitor use,(45) however, do suggest that certain other drugs within the class may induce insulin resistance directly or indirectly. Switching a protease inhibitor to abacavir,(24,46) efavirenz,(24,27) or nevirapine (24,26) appears to have a favorable effect on insulin resistance; few data exist on the effect of substituting atazanavir for another protease inhibitor. Substituting an alternative drug for a protease inhibitor may therefore be a reasonable strategy for patients with other risk factors for diabetes mellitus, such as obesity and positive family history,(47) although no data are available on the efficacy of such a strategy in preventing the development of diabetes mellitus. Because insulin resistance is associated with increased cardiovascular risk in the general population,(48) reducing insulin resistance may have long-term benefits.



Life-Threatening Toxicities

Life-threatening toxicities are rare, but remain an important reason for changing ART. Severe rash such as Stevens-Johnson syndrome or erythema multiforme is an indication to change ART.(49) These rashes have been reported most commonly with NNRTIs: delavirdine (rarely), efavirenz (0.1%), and nevirapine (1%).(50-52) Lactic acidosis is potentially fatal and is most commonly associated with stavudine, but it has been reported with all nucleoside reverse transcriptase inhibitors.(53,54) In the case of symptomatic hyperlactatemia or lactic acidosis, retrospective data suggest that it is generally safe to change the presumed offending agent (typically stavudine or didanosine) to an alternative nucleoside analogue considered to have similar virologic activity but less propensity to injure mitochondria (typically abacavir, lamivudine, or tenofovir).(55) This substitution is generally made after a treatment interruption to allow resolution of the initial toxicity. Other potentially fatal toxicities include didanosine-associated pancreatitis (56) and abacavir hypersensitivity.(57) Rechallenge with the offending agent after the onset of any of these life-threatening toxicities should not be attempted.


Adherence/Quality of Life

Much progress has been made in simplifying ART so that regimens are easier for patients to take in a consistent manner. In the mid- to late 1990s, combination ART involved taking medications at least 3 times a day, often with food and water restrictions and high numbers of pills. These complex regimens are gradually giving way to simpler regimens involving fixed-dose combination pills, newer drugs or formulations that can be taken once daily, and the use of ritonavir for pharmacokinetic enhancement of other protease inhibitors (Table 2). Given these new options, many patients with stable virologic suppression on more difficult regimens can change to regimens with lower pill burdens and minimal dosing complexity, thus improving adherence and quality of life.

Investigators have studied many approaches to simplifying complex ART regimens with the aim of improving adherence and quality of life, and thereby reducing rates of virologic failure. The most widely studied approach has been replacing a protease inhibitor with nevirapine, efavirenz, or abacavir in patients with full virologic suppression while taking a protease inhibitor-based regimen. In 2 studies, adherence improved in subjects randomized to switch from a protease inhibitor to efavirenz (58) or to abacavir (37) compared with those who continued the protease inhibitor-based regimen. In both studies, time to virologic failure was delayed in the switch arms, suggesting that the improvement in adherence was clinically relevant. Other investigators have reported improvements in quality of life, as assessed by questionnaires, in 2 randomized studies in which protease inhibitors were switched to nevirapine (59) or to either nevirapine or efavirenz (22) compared with continuing the protease inhibitor.

Clinicians who are contemplating changing an ART regimen for quality-of-life considerations should keep in mind the potential for adverse effects of the new regimen. In a large, randomized study that assessed the efficacy of simplifying protease inhibitor-based regimens by substitution with abacavir, efavirenz, or nevirapine, approximately 50% of subjects had new adverse events, although few of those events resulted in discontinuation of the regimen.(60) With the advent of several simpler protease inhibitor regimens that include options for once-daily dosing with decreased pill burden and fewer adverse effects, clinicians may have less need for the strategy of replacing protease inhibitors merely for the purpose of simplification.


Changing ART in Patients with Virologic Suppression


When considering changing an ART regimen for any of the reasons discussed above in a patient with virologic suppression, it is critical to examine the patient's treatment history. Previous virologic failure on an NNRTI, whether or not resistance testing was performed, or documented resistance to this class of agents is a contraindication to switching to nevirapine or efavirenz. Similarly, previous monotherapy or dual therapy with nucleoside analogues increases the risk of virologic failure when changing to abacavir because of selected nucleoside resistance mutations. Of note, substituting abacavir for a protease inhibitor or NNRTI typically results in a triple nucleoside regimen, which has been shown to be virologically inferior to efavirenz-based regimens as initial therapy.(61) Although switching a virologically suppressed patient to a triple-nucleoside regimen may differ from using such a regimen as initial treatment, a randomized simplification trial in which subjects on protease inhibitors were switched to abacavir, nevirapine, or efavirenz showed a trend toward a greater rate of virologic failure in the abacavir arm.(60) Thus, drug substitution that results in a triple-nucleoside combination without additional drugs cannot be recommended for most patients.


Concomitant Medical Conditions

A patient's changing clinical status often mandates a change in ART. For example, certain antiretroviral medications are less favored in pregnancy. Efavirenz is teratogenic in animals and was linked to birth defects in several reported cases,(62,63) so this agent should be substituted with nevirapine or an appropriate protease inhibitor-based regimen in pregnant women.(63) Caution should be used with nevirapine in pregnancy because it has been associated with an increased risk of fatal hepatitis in pregnant women, especially in women with higher CD4 counts; nevirapine generally should not be initiated in women whose CD4 count is >250 cells/µL.(64) The oral solution of amprenavir should not be used in pregnant women because of the high content of polyethylene glycol,(65) and hyperbilirubinemia induced by atazanavir and indinavir is a theoretical risk for the newborn.(66,67)

Medications used to treat comorbid illnesses often interact with antiretroviral agents. A prime example is the interaction of rifampin, a first-line drug for the treatment of tuberculosis, with both NNRTIs and protease inhibitors.(68) This interaction may be avoided by substitution of efavirenz for nevirapine, perhaps by dose adjustment of efavirenz,(69) or by substitution of rifabutin for rifampin in the case of protease inhibitors.(68) Other important drug interactions include cholesterol-lowering "statins" with protease inhibitors,(70) oral contraceptives with NNRTIs or protease inhibitors,(71) and ergot derivatives with protease inhibitors.(72) The activity of tenofovir, emtricitabine, and lamivudine against hepatitis B has encouraged many providers to include these medicines in the ART regimens of patients with chronic hepatitis B.(73-75) (See chapter "Coinfection with Hepatitis Viruses and HIV.")


Suboptimal Immunologic Response

Patients starting ART may fail to have a significant increase in CD4 cells despite control of viral replication. Investigators from the Swiss HIV Cohort Study reported that 38% of patients with stable suppression of HIV during ART for >5 years failed to reach a CD4 count of at least 500 cells/µL.(76) In some cases, the particular ART regimen may be problematic; several studies have shown suboptimal increases, or even decreases, in the CD4 count in patients treated with virologically suppressive ART regimens that include the combination of didanosine and tenofovir.(77,78) Generally, however, the causes and clinical significance of this phenomenon are unclear, but remain a concern for both patient and provider. Treatment intensification (supplementing an existing regimen with additional antiretroviral drugs) in the setting of poor CD4 recovery has not been shown to increase the CD4 count.(79) Interleukin-2 has been shown to increase CD4 cells, but its relationship to clinical outcomes has been lacking and adverse effects are common.(80) The Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT) study is a large ongoing trial that is assessing clinical end points (eg, death, new opportunistic infections) with subcutaneous interleukin-2 versus placebo in patients taking ART. However, this study is limited to individuals who have CD4 counts >300 cells/µL at baseline. Without additional data, the best strategy for patients with virologic suppression and suboptimal immunologic response is probably to continue their current regimens.


HIV-Related Clinical Events


Clinical events such as opportunistic infections or AIDS-associated malignancies are uncommon in patients with virologic suppression during ART. The ART Cohort Collaboration, involving 13 cohort studies of patients starting a first ART regimen, estimated the risk of an AIDS-defining illness or death within 3 years of starting ART. Among those patients with virologic suppression 6 months after starting ART, the estimate of risk ranged from 14% for those with a 6-month CD4 count of <25>350 cells/µL.(81,82) Limited data are available on whether to change ART for patients who develop AIDS-defining illnesses. Certainly, a regimen should be changed if the patient has detectable viremia and if viable alternatives exist to ensure maximal suppression of HIV and to enhance immune reconstitution. Other infections such as herpes simplex virus reactivation, herpes zoster, pneumonia, and human papillomavirus-associated squamous intraepithelial lesions (eg, cervical and anal dysplasia) can occur in patients with stable virologic suppression during ART and do not indicate a need for changing ART.

Caution should be used in interpreting clinical events that occur soon after the initiation of ART (eg, within 3 months). During this period, patients starting ART with lower CD4 cell counts, especially <100>Changing ART for Virologic Failure

The treatment guidelines of the U.S. Department of Health and Human Services suggest criteria for assessing virologic failure: HIV RNA >400 copies/mL at 24 weeks of therapy, HIV RNA >50 copies/mL by 48 weeks of ART, or repeated detection of viremia after virologic suppression.(71) A single elevated HIV RNA level should be confirmed with a second measurement because an isolated increase ("blip") in HIV RNA may occur in up to 40% of patients and is not associated with virologic failure.(84) However, repeated or sustained increases in HIV RNA levels are associated with an increased risk of virologic failure.(85)


Cause of Failure

Once a patient has experienced virologic failure, the cause of the failure should be explored. If adherence, toxicity, and pharmacokinetic reasons can be excluded, then virologic failure of the current regimen has been established. The initial approach to treatment failure is to carefully review the patient's antiretroviral history, including each specific drug (noting the formulation) and each previous regimen, the duration of each regimen, any adverse effects or toxicities, and the response in HIV RNA levels and CD4 cell counts (if known). This information is essential for assessing the likelihood of archived resistance mutations to individual drugs or drug classes. The patient should be encouraged to continue the current regimen during the assessment of virologic failure because discontinuing ART, even in the setting of virologic failure, may lead to both a rapid increase in HIV RNA level and a decrease in CD4 cell count, with or without clinical events.(86)


Resistance Testing

Resistance testing gives information only about the most prevalent viral strain circulating at the time the blood specimen is obtained. Therefore, resistance testing should be performed while the patient is taking the failing treatment regimen, because virus that harbors resistance mutations may not be detected readily after the selective pressure of drug is removed, but nevertheless will remain archived in tissue reservoirs. In separate studies, both genotypic testing (87,88) and phenotypic testing (89) led to significantly improved virologic responses with the subsequent ART regimen as compared with the strategy of using the antiretroviral history alone in selecting the regimen. (See chapter "Genotypic Testing for HIV-1 Drug Resistance.") Although current guidelines recommend the use of resistance testing in the management of antiretroviral failure,(71,90) it is not clear whether the optimal test is a genotype, a phenotype,(91) or both.(92) Used together, a careful ART history and resistance testing yield the most complete assessment of both archived and present resistance mutations, and this strategy optimizes selection of the next ART regimen.


Expert Advice

Evaluation and management of antiretroviral-experienced patients are complicated. Because HIV clinicians may have limited knowledge about resistance testing,(93) expert advice is recommended. In the Havana study, resistance testing and expert advice for selecting subsequent ART regimens were each associated with improved virologic responses.(94) Current guidelines suggest obtaining expert advice when managing treatment-experienced patients.(71)


Pharmacokinetics


Drug concentrations are associated with virologic responses in treatment-experienced patients. For example, as part of the Viradapt study, protease inhibitor concentrations were measured in patients taking combination regimens and were assessed as optimal or suboptimal (<2-fold>Selecting the Next Regimen.

For a patient experiencing virologic failure, how is the next ART regimen optimally designed? The initial approach was simply to use drugs that the patient had not yet taken, but in early clinical studies such as AIDS Clinical Trials Group studies 359 and 398, this strategy achieved maximal virologic suppression in only about 30% of patients.(101,102) However, these early studies did suggest factors that were associated with better virologic responses, including a lower baseline HIV RNA level at the time of regimen change; use of 2 protease inhibitors, rather than 1, in the next regimen; and use of a new class of agents (eg, NNRTIs). The initial studies of resistance testing also led to the recommendation that the new ART regimen for a patient experiencing virologic failure should contain at least 3 active (on the basis of resistance testing) antiretroviral agents to achieve an optimal virologic response.(71,87)

One study incorporated several of these factors in its design by enrolling 70 patients who had experienced failure of only 1 protease inhibitor, had not taken NNRTIs, and had HIV RNA levels ranging from 1,000 copies/mL to 100,000 copies/mL.(103) The subjects substituted lopinavir/ritonavir (at either of 2 randomly assigned doses) for their current protease inhibitor and also added nevirapine (introducing a new drug class for these subjects) and at least 1 new nucleoside analogue.(103) At 48 weeks in an intent-to-treat analysis, 70% of subjects had HIV RNA levels <400>

Conclusions

Changing an ART regimen is common in clinical practice for patients with either suppressed virologic replication or virologic failure. Those with virologic suppression usually have changes in ART in an attempt to alleviate acute toxicities, control chronic toxicities, or improve quality of life. This strategy generally appears safe as long as relevant issues such as previous ART use are considered. The benefits of changing ART must be weighed against the possibilities of encountering new toxicities and increasing the risk of virologic failure. The management of virologic failure among treatment-experienced patients has improved over the last several years. The establishment of clear criteria for assessing virologic failure, the development and availability of HIV resistance testing, the identification of factors leading to improved virologic responses in subsequent regimens (eg, 3 active drugs in the regimen), the development of new antiretroviral agents with activity against resistant virus, and the exploration of therapeutic drug monitoring have contributed to progress in the field.

Nutrition and HIV

Source : http://www.thebody.com/content/living/art2516.html
(You can read this website for more informations and reference.)

San Francisco AIDS Foundation

By Liz Highleyman

Winter 2005/2006

Good nutrition is key to a healthy lifestyle, regardless of whether one is living with HIV/AIDS. Optimal nutrition can help boost immune function, maximize the effectiveness of antiretroviral therapy, reduce the risk of chronic illnesses such as diabetes and cardiovascular disease, and contribute to a better overall quality of life.
In the early years of the AIDS epidemic, many people with HIV were dealing with wasting and opportunistic infections (OIs) linked to unsafe food or water. While these problems are less common today in developed countries with widespread access to highly active antiretroviral therapy (HAART), many HIV positive people have traded these concerns for worries about body shape changes, elevated blood lipids, and other metabolic complications associated with antiretroviral therapy.

Fortunately, maintaining a healthy diet can help address these problems. As HIV positive people live longer thanks to effective treatment, good nutrition can also help prevent problems (such as bone loss) associated with normal aging. But there is no single, optimal eating regimen appropriate for every person living with HIV/AIDS. Instead, HIV positive people should adopt a sensible balanced diet and consult an experienced nutrition specialist for individualized recommendations.

Food for Life
Food is essential for life, providing the fuel the body needs to function and the building blocks that make up cells, tissues, and organs. The energy provided by food is expressed in terms of calories. The body requires a certain number of calories simply to carry out its basic metabolic functions such as respiration and maintenance of body temperature. Additional calories are needed to support physical activity, fight infection, and rebuild damaged tissues.
If a person does not take in enough calories, fat is broken down to provide fuel. Once the fat is consumed -- or if an individual's metabolism is disrupted due to illness -- lean body mass (muscles and organs) is then used for fuel and raw materials. Conversely, if a person takes in more calories than needed, the extra energy will be stored as fat. The average person needs about 10-20 calories per pound (depending on physical activity level and other factors) to maintain a stable body weight; this requirement is likely to be higher for people with HIV, especially those with advanced disease.

But all food is not equal. While all contain calories, different foods vary widely in the nutrients they provide. A balanced diet is comprised of the following components.

Protein: Protein provides the building blocks of lean body mass. When a protein-rich food is consumed, it is broken down into amino acids, which are reassembled to create enzymes, hormones, and bodily tissues. Most nutrition experts recommend that protein should contribute about 15-20% of the total calories in a person's diet. Good sources include meat, poultry, fish, eggs, dairy products, tofu, nuts, and legumes (e.g., dried beans, lentils).

Carbohydrates: Carbohydrates, which are converted to glucose in the body, are a primary source of energy. Carbohydrates are classified as simple or complex; complex carbohydrates take more time to break down, and thus provide fuel over a longer period of time. Despite the recent popularity of "low carb" diets, most nutrition experts recommend that carbohydrates -- primarily complex ones -- should make up at least 50% of one's total daily calorie intake. Simple carbohydrates are found in processed sugar, honey, fruit and juice, and lactose (milk sugar). Complex carbohydrates are found in grain products such as bread, pasta, and rice; legumes; and starchy foods such as corn, potatoes, winter squash, and root vegetables.

Fats: Fat in food is a source of energy and has a high concentration of calories. Excess energy from any source -- not just fatty food -- is converted to fat in the body and stored for later use. Cholesterol (found in animal products like meat and eggs) and triglycerides are present in food, but are also produced when the body metabolizes sugar and saturated fat. Everyone needs some dietary fat, but getting too little is rarely a problem. More important is the type of fat. Saturated fats promote elevated blood levels of low-density lipoprotein (LDL) "bad" cholesterol, which can clog arteries and increase the risk of cardiovascular disease. Saturated fat is found in meat, butter, tropical oils (e.g., coconut, palm), and "trans" fats or hydrogenated oils (which are chemically altered to make them solid at room temperature). Polyunsaturated fats (found in safflower, sunflower, corn, and soybean oils) are generally considered more healthful, and monounsaturated fats (found in olive and canola oils, nuts, seeds, and avocados) can help raise levels of high-density lipoprotein (HDL) "good" cholesterol, which protects against heart disease. A balanced diet also contains essentially fatty acids, including omega-3 (found in flax and cold-water fish). Most experts say fats should make up no more than 25-30% of total calorie intake, with less than 10% being saturated fat.

Fiber: Also known as "roughage," fiber is indigestible plant matter such as cellulose. Insoluble fiber plays an important role in digestion, helping food move smoothly through the colon (large intestine); this type of fiber is found in the skin and pulp of many fruits and vegetables, whole grains, popcorn, and seeds. Soluble fiber helps stabilize blood sugar and may reduce LDL cholesterol levels; this type of fiber is found in oatmeal and oat bran, legumes, nuts, and fruits such as apples, oranges, pears, and grapes.

Vitamins and minerals: Along with the "macronutrients" described above, a balanced diet also contains many "micronutrients," organic and inorganic substances necessary for proper biological functioning. Water-soluble vitamins (B and C) are excreted in the urine and must be consumed more often; fat-soluble vitamins (A, D, E, and K) are stored in the liver and can reach toxic levels if taken in large doses. Most vitamins must be obtained from food, although the body manufactures vitamin D when the skin is exposed to sunlight and others are produced by bacteria in the gut. Minerals (including the electrolytes chloride, potassium, and sodium) are inorganic substances found in the environment. The body needs several trace elements in tiny amounts, including boron, chromium, cobalt, copper, iodine, manganese, molybdenum, selenium, and zinc. Cooking and processing can destroy some vitamins and minerals. For information on the function and food sources of specific vitamins and minerals, see the chart below.

Antioxidants: Free radicals are unstable oxygen molecules that contain unpaired electrons. This allows them to set off damaging chain reactions when they bind with and "steal" electrons from other molecules in the body -- a process known as oxidative stress. Antioxidants scavenge and neutralize free radicals. By disrupting the oxidation process, antioxidants help protect cells from damage. Antioxidants include vitamins C and E, beta-carotene, the minerals selenium and zinc, and glutathione.

Phytochemicals: Among the advantages of obtaining nutrients from a balanced diet rather than supplements is that there are substances in whole foods that may offer unrecognized benefits. While most vitamins and minerals were isolated early in the 20th century, plant compound called phytochemicals are just now being discovered. Among these are allyl sulfides (found in garlic and onions), anthocyanins (in blueberries and blackberries), carotenoids (including beta-carotene in orange fruits and vegetables, lycopene in tomatoes, and lutein in dark green leafy vegetables), catechins (the tannins in green and black tea), flavonoids (in dark chocolate, red wine, tea, and many fruits), isothiocyanates (in broccoli and other cruciferous vegetables), limonoids (in citrus fruits), and sulforaphane (also in cruciferous vegetables). Some phytochemicals work as antioxidants, but others appear to have different mechanisms of action.

How HIV Impacts Nutrition ... and Vice Versa
In the early years of the epidemic, healthcare providers soon learned that people with AIDS commonly experienced both overt protein/calorie malnutrition and deficiencies of specific nutrients. But nutrient depletion may also begin to occur earlier in the course of HIV disease, even among individuals with relatively intact immune systems. Several factors can contribute to nutritional problems in people with HIV/AIDS.
Malabsorption: HIV or associated infections can damage the lining of the gastrointestinal tract, which can interfere with absorption of nutrients. Some HIV positive people experience specific problems, such as fat malabsorption, which can impair absorption of fat-soluble vitamins.

Opportunistic infections: Various bacterial, viral, fungal, and parasitic infections can interfere with proper nutrition. Malignancies (cancers) and mycobacterial illnesses such as tuberculosis are often characterized by wasting. Several OIs cause vomiting and diarrhea, which can lead to poor absorption or loss of nutrients. Other infections -- such as thrush (oral candidiasis), gingivitis (gum inflammation), and cytomegalovirus esophagitis (throat inflammation) -- can make eating painful.

Medications: Antiretrovirals, OI drugs, and other medications can contribute to nutrient deficiencies and imbalances, either due to direct drug-nutrient interactions or drug side effects. Vomiting and diarrhea can lead to dehydration and depletion of nutrients. Loss of appetite (anorexia), fatigue, and taste alterations can make it difficult to eat enough. Antibiotics may interfere with nutrition by killing off beneficial bacteria in the gut. Food requirements -- the need to take medications either on a full or an empty stomach or with specific types of food -- can disrupt normal eating patterns. Finally, some antiretroviral medications are associated with metabolic changes such as blood lipid and glucose abnormalities.

Inadequate intake: Ill people often experience anorexia. OI symptoms and medication side effects -- nausea, diarrhea, sore mouth or throat, altered sense of taste or smell -- can further reduce the desire or ability to eat. This may be compounded by lack of money, depression, or feeling too fatigued to shop and prepare food.

Altered nutritional requirements: By altering metabolism (how the body processes and uses nutrients), acute or chronic illness -- including HIV disease and OIs -- and the resulting immune response can increase the body's energy needs. People with HIV/AIDS may require more calories, macronutrients, and specific vitamins and minerals. Chronic illness may also alter hormone and cytokine levels, which may have nutritional implications.

Conversely, nutritional deficiencies can impair immune function, potentially worsening HIV disease progression. Research has shown that depletion of vitamins A, C, and E, the B-complex vitamins, and the minerals selenium and zinc can interfere with cell-mediated immunity (CD4 cell, natural killer cell, and neutrophil proliferation and activation), antibody production, and normal cytokine signaling.

Studies looking at the prevalence of nutritional deficiencies in people with HIV/AIDS have produced conflicting data, but on the whole, depletion of nutrients (e.g., vitamins A and E, and minerals including magnesium, selenium, and zinc) appears to be common, especially among individuals with advanced disease. In particular, having HIV seems to decrease the body's store of antioxidants, as they are needed to offset increased oxidative stress. Researchers have uncovered evidence of subtle nutritional deficiencies among people who appear to be eating an adequate diet and are not suffering from frank protein/calorie malnutrition.

Experts don't yet understand the clinical significance -- if any -- of subtle changes in laboratory values relative to the norms seen in the HIV negative population, nor do they know how much of any given nutrient people with HIV/AIDS need for optimal immune function and overall health. Due to a lack of research on nutritional status in the setting of HIV disease, and because nutritional requirements vary dramatically from person to person, there are few definitive recommendations for nutritional supplementation in the HIV positive population.

Waste Not, Want Not
Wasting -- also known as cachexia -- was a prominent feature of AIDS in the early years of the epidemic; even today, AIDS is referred to as "slim disease" in Africa. Experts define wasting as involuntary or unwanted loss of 10% or more of body weight. As Steven Grinspoon, MD, and Kathleen Mulligan, MD, discuss in an April 2003 special issue of Clinical Infectious Diseases (CID) devoted to nutrition and HIV, "wasting ... has been associated with increased mortality, accelerated disease progression, loss of muscle protein mass, and impairment of strength and functional status." Even a 5% loss has been linked to increased illness and death.
In classic HIV-related wasting, lost weight is in the form of lean body mass rather than fat, especially in men. People with HIV/AIDS (and other chronic illnesses) require more calories simply to maintain their weight, due to increased metabolism, higher energy demands, hormone and cytokine imbalances, inefficient absorption and utilization of nutrients, and/or accelerated tissue breakdown (catabolism).

While effective antiretroviral therapy has dramatically reduced the incidence of severe wasting, moderate weight loss is still a prominent feature of HIV disease. For example, as reported in the September 1, 2005 Journal of Acquired Immune Deficiency Syndromes (JAIDS), Alice Tang, MD, from Tufts University Medical School and colleagues found a steady increase in the rate of 5% or greater loss of body weight between 1995-1997 (pre-HAART) and 1998-2003 (HAART era). In an analysis of 713 HIV positive participants in the Nutrition for Healthy Living cohort, 53% lost at least 5% of their body weight during any six-month period. Weight loss was significantly associated with nausea, diarrhea, thrush, poverty, history of drug use, CD4 cell count below 200 cells/mm3, and HIV viral load above 100,000 copies/mL. The authors were unable to pinpoint the reasons for the increased rate of wasting in the HAART era.

In another study (reported in the October 15, 2005 issue of CID), Adriana Campa, PhD, from Florida International University and colleagues found that 17.6% of 119 HIV positive, mostly homeless drugs users in Miami showed evidence of HIV-related wasting. In this study, wasting was associated with cocaine and heavy alcohol use, "food insecurity" (not eating for one or more days in the past month), and higher HIV viral load. Participants taking HAART were more likely to experiencing wasting than those not receiving anti-HIV treatment (86% vs 67%).

Rather than dramatic whole-body weight loss, today many HIV positive people on HAART experience lipoatrophy, or fat loss in the face, limbs, and buttocks. Paradoxically, this may coincide with fat accumulation in other areas of the body (discussed below). Lipoatrophy is most strongly associated with use of nucleoside reverse transcriptase inhibitors (NRTIs), especially d4T (stavudine or Zerit). For this reason, U.S. government treatment guidelines no longer recommend d4T as part of a first-line regimen for people starting HAART.

Since HIV positive people and their clinicians may not recognize the early signs of wasting, it is important to monitor weight regularly to detect subtle changes. Underlying factors contributing to weight loss -- such as OIs or hormone imbalances -- should be promptly addressed. But, as Grinspoon and Mulligan point out, "no therapeutic guidelines currently exist for the management of weight loss and wasting in HIV-infected patients."

When it comes to weight loss, prevention is often easier than cure. To add calories, focus on proteins and complex carbohydrates rather than "junk food" that contains mostly sugar and fat. Consider eating several small meals and snacks throughout the day rather than two or three large meals. Nutritional supplements such as Ensure or Boost may benefit individuals who find it difficult to eat solid foods. Some cities offer food delivery programs for people with HIV/AIDS who are unable to shop or prepare meals (e.g., Project Open Hand in San Francisco, God's Love We Deliver in New York City, Moveable Feast in Baltimore).

The appetite stimulant megestrol acetate (Megace) tends to promote fat rather than muscle gain and can cause side effects including edema (swelling). Certain antidepressants and other medications may also enhance appetite. Some patients swear by medical cannabis or dronabinol (Marinol), a pill that contains a synthetic version of marijuana's active ingredient, THC.

While recombinant human growth hormone (HGH, Serostim) is FDA-approved for the treatment of HIV-related wasting, it is extremely expensive and can cause side effects including carpal tunnel syndrome, joint pain, and insulin resistance. Anabolic (muscle-building) steroids such as testosterone and oxandrolone (Oxandrin) help some patients gain weight, but can also cause adverse effects. Hormone replacement therapy is most useful for individuals who have low levels; there is little evidence that "supraphysiological" doses (higher than the natural physiological range) are beneficial, and they may be harmful (see "HIV and Hormones" in the Summer 2004 issue of BETA). Research has shown that anabolic steroids work better when combined with resistance exercise; in fact, some studies suggest resistance exercise works better than steroids, without the cost or side effects.

Weights and Measurements
Body weight alone is not the best indicator of body composition. Various other metrics can give a better sense of relative proportions of lean body mass and fat. Each method has its pros and cons; ask your healthcare provider which are most appropriate given your individual situation.

Body mass index (BMI): an equation that relates weight to height (weight in kilograms divided by height in meters squared). BMI below 18.5 indicates that a person is underweight; 18.5-24.9 is normal weight; 25.0-29.9 is overweight; and 30.0 or above is obese.

Waist-to-Hip Ratio: waist measurement (at the narrowest point) divided by hip measurement (at the widest point). Weight carried around the waist (an "apple" shape) is associated with greater cardiovascular risk than weight distributed around the hips and thighs (a "pear" shape). A healthy waist-to-hip ratio is below 0.9 for men or 0.8 for women. This measure may not be appropriate for HIV positive individuals with lipodystrophy.

Bioelectrical impedance analysis (BIA): a technique for determining body composition using a mild electrical current that travels more easily through muscle than fat.

Skinfold thickness: a technique that uses calipers to assess the amount of subcutaneous fat under the skin at multiple sites.

Hydrostatic weighing: a technique for assessing body density in which a person's weight measured when dry is compared to his or her underwater weight, accounting for residual air in the lungs and gastrointestinal tract.

Magnetic resonance imaging (MRI): a noninvasive method for viewing soft tissues of the body using a magnetic field.

Dual-energy X-ray absorptiometry (DEXA): an X-ray technique used to measure body composition, including proportion of fat and bone mineral density.

Computerized tomography (CT or CAT scans): a method of visualizing tissues of the body using X-rays.

Too Much of a Good Thing
For many HIV positive people in the developing world today, severe overall wasting due to protein/calorie malnutrition is not a major concern. In fact, some research suggests obesity may be a bigger problem. For example, Valerianna Amorosa, MD, and colleagues from the University of Philadelphia reported in the August 15, 2005 issue of JAIDS that in a cohort of nearly 1,700 HIV positive individuals, 31% of men and 30% of women were overweight, and 11% and 28%, respectively, were obese (in contrast, just 9% overall experienced wasting). Obesity was not associated with age, income, employment status, education, history of injection drug use, HIV treatment, or viral load, but in women it was more common among African-Americans. In Tang's study discussed above, the proportion of patients categorized as overweight was greater in the HAART era than before the advent of effective antiretroviral therapy (35% vs 30%). And HIV positive people are hardly alone: the National Center for Health Statistics reports that two-thirds of all Americans are overweight and nearly one-third of adults are obese -- double the proportion in 1980.
While "garden variety" obesity remains common, HIV positive people on HAART may also experience accumulation of fat in specific areas of the body including the belly, breasts, and back of the neck ("buffalo hump"). This abdominal or truncal lipohypertrophy is composed of deep visceral fat surrounding the internal organs. Both lipoatrophy (described above) and lipohypertrophy are features of lipodystrophy syndrome; however, as discussed in an article by Denise Jacobson, PhD, and colleagues from Tufts in the June 15, 2005 issue of CID, experts now recognize that these are two distinct processes, not simply redistribution of fat from one area to another.

Lipodystrophy syndrome also includes elevated blood lipid levels and blood glucose abnormalities (see "Insulin Resistance and Diabetes" in the Winter 2004 issue of BETA). While most research indicates that lipodystrophy is associated with antiretroviral therapy -- in particular protease inhibitors (PIs) -- it is likely a multifactorial condition related to long-term HIV infection or immune reconstitution, since some people who develop the syndrome have never taken HAART. In a recent study by Peter Bacchetti, PhD, and colleagues, for example, abdominal fat accumulation was not linked to HAART, and was actually more common among HIV negative than HIV positive men (see "News Briefs," in this issue.)

Obesity, and in particular visceral abdominal fat, has been linked to increased risk of cardiovascular disease in the general population. While it is still uncertain whether HIV positive people on HAART have higher rates of heart attacks and strokes (studies have yielded mixed data), it is likely that traditional cardiovascular risk factors -- advancing age, male sex, cigarette smoking, high LDL cholesterol and triglyceride levels, insulin resistance, elevated blood pressure, and being overweight -- are as important for HIV positive people as for anyone else (see "Cardiovascular Disease in People with HIV" in the Summer/Autumn 2002 issue of BETA).

While early nutritional guidelines for people with AIDS often emphasized packing on the calories -- adding cream, cheese, peanut butter, gravy, and the like to foods -- many HIV positive people today would be better served by adopting a balanced, low-fat diet.

Lifestyle changes, including diet modification, weight loss (if needed), exercise, and smoking cessation, are the first line of defense against cardiovascular disease. In order to lose weight, HIV positive people must follow the same rules as everyone else: burn more calories than one takes in. But reducing the amount of fat and cholesterol in the diet is not always enough to reverse fat accumulation or bring blood lipids within a healthy range, and exercise may not have much effect on visceral fat. When this is the case, lipid-lowering medications (including the statin and fibrate classes) are often used. Altering one's antiretroviral regimen to include drugs less linked to high blood fat -- such as substituting atazanavir (Reyataz) for another PI -- is often effective. Researchers have tried treating lipodystrophy with human growth hormone and anabolic steroids, with mixed results. Although it is not yet clear what are the best interventions to address increased cardiovascular risk among HIV positive people on HAART, experts agree that a healthy diet certainly can't hurt, and is likely to be part of the solution.

Healthy Diet Basics
A healthy diet provides adequate nutrition without a lot of empty calories. "Balanced" means eating a variety of foods from all the important food groups, since no food alone provides all the nutrients the body needs. The traditional Food Guide Pyramind offers guidelines about how much to eat from each food group. (The traditional food pyramid was replaced in 2005 with a new pyramid, an online tool at www.MyPyramid.com. Because the new pyramid is more difficult to interpret, however, many nutrition experts continue to use the traditional version.) It recommends 6-11 servings per day of grain products such as bread, cereal, rice, and pasta; 3-5 servings of vegetables; 2-4 servings of fruit; 2-3 servings of dairy products such as milk, yogurt, and cheese; 2-3 servings of high-protein foods such as meat, poultry, fish, eggs, and legumes; and small amounts of fat, oil, and sugar.
This may seem like a lot, but a "serving" is smaller than many people realize. A "serving" as per the guidelines would be, for example, a 3-ounce portion of cooked meat (about the size of a deck of playing cards), one chicken leg, a 2-inch cube of cheese, an 8-ounce glass of milk, a single tortilla or slice of bread, 5-6 crackers, one-third cup of cooked pasta, one-half cup of cooked vegetables, or one medium-size apple or orange. The amount of food typically served in restaurants, therefore, actually accounts for multiple "servings."

The 2005 revision of the food pyramid focuses less on quantity and more on quality, while also emphasizing the importance of physical activity. At least half of one's daily consumption of bread and cereal products should be comprised of whole grains; as a rule, less processed foods contain more nutrients. Simple carbohydrates tend to make blood glucose spike soon after eating and then fall, while complex carbohydrates tend to promote more stable levels over time. But what really matters is a food's "glycemic index," a measure of how quickly it is broken down in the body. Foods with a high glycemic index are broken down rapidly, causing blood sugar to rise sharply, while low glycemic index foods help the body maintain a steadier glucose level.

Eat vegetables of various colors -- including dark green and deep orange -- since these contain different vitamins, minerals, and phytochemicals. Whole fruit is preferable to juice, which is high in sugar and calories and typically lacks fiber. Since cooking can destroy vitamins, it is usually recommended to eat vegetables raw or lightly steamed. However, this may not be the best advice for people with severely compromised immunity who are at risk of infection with microorganisms that can be killed by cooking.

In the dairy group, select low-fat or non-fat products. People who choose not to consume dairy foods should be sure to obtain enough calcium from other sources. In the protein group, the new pyramid recommends eating more legumes, nuts, seeds, and fish -- which contains heart-healthy omega-3 fatty acids. When eating meat or poultry, remove visible fat and skin. Broiling, baking, and grilling are healthier cooking methods than frying.

In terms of fats, avoid animal-derived fats and chemically altered hydrogenated oils, instead substituting plant-derived monounsaturated and polyunsaturated oils. This is good advice even for people who do not need to lose (or could stand to gain) weight, since animal fats increase the risk of cardiovascular disease. Fortunately, thanks to consumer demand, it is easier than ever to find commercial baked goods, snack foods, salad dressings, and the like that do not contain saturated fats. Another boon for the heart: a low-sodium diet can help keep blood pressure under control.

In addition to eating a balanced diet, it is also important to consume enough fluids. Experts traditionally recommend eight 8-ounce glasses of water per day. Herbal tea, broth, and fruit or vegetable juices can also be good fluid sources. But beverages that contain caffeine or alcohol have a diuretic effect, and can cause loss of water due to increased urination. It is especially important to drink enough fluid to prevent dehydration when suffering prolonged vomiting or diarrhea. People with very low CD4 cell counts concerned about infections such as cryptosporidiosis due to contaminated tap water should use filtered or bottled water.

Facts Versus Fads
The traditional dietary guidelines are not free of controversy. Some critics contend that in putting together the recommendations, the federal government has been unduly influenced by the food industry. They argue, for example, that adults really do not need to consume cow's milk at all. Some believe the pyramid recommends more protein than most people need, while others argue that humans evolved to eat a "hunter-gatherer" diet much lower in carbohydrates.
"Low carb" diets (related to the Atkins plan) containing small amounts of carbohydrates and larger amounts of protein and fat have gained considerable popularity in recent years -- so much so that many people have come to believe that carbohydrates per se are "fattening." While such diets may produce temporary weight loss, they are usually short on fiber, can stress the liver and kidneys, and may lead to dangerously elevated blood lipid levels.

More people are also adopting vegetarian or vegan diets, which have been linked to reduced risk of cardiovascular disease and cancer. Most people can obtain adequate nutrition from a diet that contains little or no meat or other animal products, though this may be more challenging for growing children or people with chronic illness who have increased energy needs. The trick is to learn how to combine proteins from different sources (such as grains, legumes, nuts, and soy) to obtain a full complement of essential amino acids; vitamin B12 supplementation may also be needed.

An increasing number of healthcare providers now recommend a "Mediterranean diet" -- including olive oil, tomatoes, garlic, and red wine -- since people from areas that consume such a diet tend to have lower rates of heart disease. A Japanese-style diet that contains lots of fish and soy products is also a healthy option.

Notwithstanding these caveats, the consensus recommendation to eat a range of foods from a variety of categories remains sound. Most experts suggest a breakdown of about 50-60% carbohydrates, 15-20% protein, and no more than 25-30% fat. But because individual nutritional needs vary widely, it is difficult to recommend a specific diet suitable for all people with HIV/AIDS. A trained dietitian who has experience working with HIV positive people can help devise an appropriate individualized eating plan.


Learn how to read the "Nutrition Facts" label, which contains a wealth of information about the nutritional content of packaged foods: www.cfsan.fda.gov/~dms/foodlab.html.

What About Supplements?
As a rule, it's usually best to obtain nutrients from food. Swallowing handfuls of pills will not make up for a poor diet. But even HIV positive people who eat well can have low levels of various important nutrients -- at a time when their nutritional needs may be increased -- and thus may benefit from supplementation. The U.S. government's Daily Values (formerly known as Recommended Dietary Allowances) for nutrients do not necessarily reflect the amount required for optimal health, just the minimum needed to stave off deficiency symptoms in the average healthy person. It is not yet known whether accepted recommended nutrient levels for the general population are adequate for people with HIV/AIDS.
Dietary supplements are products such as vitamins, minerals, amino acids, herbs, and antioxidants; they are usually taken orally in the form of tablets, capsules, powders, or liquids. Due to the lack of strict quality control and labeling requirements, marketed products can vary widely in contents, strength, and purity. Although regulated by the U.S. Food and Drug Administration (FDA), supplements do not need to undergo rigorous clinical trials of safety and efficacy as required for approval of pharmaceutical drugs. In fact -- because there is little financial incentive to spend money developing products that cannot be patented -- there have been few rigorous, controlled studies on the use of nutritional supplements in people with HIV.

In the mid-1980s, Barbara Abrams, DrPH, and colleagues from the University of California at Berkeley began a large observational study of dietary intake in 296 HIV positive men; results were reported in the August 1993 issue of JAIDS. By one measure, the risk of developing AIDS decreased as consumption of 11 different micronutrients increased -- significantly so for riboflavin, vitamin E, and iron, and approaching significance for thiamin, niacin, and vitamin C. This study was susceptible to selection bias, however, since people who ate healthier diets or took supplements might have had healthier lifestyles overall.

More recently, researchers in Thailand showed that a low-cost multivitamin and mineral supplement improved the survival of HIV positive people who were not taking HAART. As reported in the November 21, 2003 issue of AIDS, Sukhum Jiamton, MD, and colleagues conducted a double-blind, placebo-controlled trial in which nearly 500 HIV positive individuals with CD4 cell counts of 50-550 cells/mm3 were randomly assigned to receive either a placebo or a supplement containing 12 vitamins, eight minerals, and the amino acid cysteine twice daily. After 48 weeks, about twice as many people died in the placebo arm compared with the supplement arm (15 vs 8 deaths); among those with baseline CD4 counts below 200 cells/mm3, the mortality rate was significantly lower in the supplement arm. On the other hand, an earlier study in Zambia found that multivitamin supplementation had no effect on CD4 cell count or mortality.

In the July 1, 2004 New England Journal of Medicine, Wafaie Fawzi, DrPH, from Harvard School of Public Health and colleagues reported on a double-blind, placebo-controlled study in which 1,078 HIV positive pregnant women in Tanzania received either daily supplements of vitamin A; a multivitamin supplement containing vitamins B, C, and E; or both. After a median follow-up of 71 months, 67 out of 271 women (24.7%) who received the multivitamin either died or progressed to advanced HIV disease (stage IV as defined by the World Health Organization), compared with 83 out of 267 women (31.1%) who received the placebo. Women in the multivitamin arm -- but not those receiving vitamin A alone -- also had significantly lower HIV viral load, higher CD4 and CD8 cell counts, and improved birth outcomes.

In a June 10, 2005 AIDS editorial reviewing the current state of knowledge about micronutrient supplementation in people with HIV/AIDS, Tang and colleagues concluded that "a combination of vitamins may afford some benefits to undernourished HIV-infected populations, particularly those with more advanced disease," but conceded that "the role of individual micronutrients ... is less clear." Most healthcare providers agree that HIV positive people can benefit from a daily multivitamin and mineral supplement. (Due to the potential harmful effects of iron, many recommend an iron-free supplement for anyone other than menstruating women and people with iron deficiency). But when it comes to specific nutrients, expert opinion -- and the little relevant research conducted to date -- remains sharply divided.

Higher amounts of various substances have been proposed to improve immune response, ameliorate symptoms and drug side effects, and slow HIV disease progression, on the basis of theoretical understandings about how an agent is expected to behave, laboratory research looking at the effects of a substance in vitro, cross-sectional studies showing specific nutritional deficiencies in a population, or -- less commonly -- controlled trials. Several nutrients that have received the most attention with regard to HIV/AIDS are discussed below.

"[A]ddressing obesity is likely to become an increasingly common part of the management of HIV infection."

-- David Wohl, MD

Vitamin A
Richard Semba, MD, from Johns Hopkins and colleagues reported in 1993 that among a cohort of 179 HIV positive and HIV negative injection drug users in Baltimore, vitamin A deficiency was linked to lower CD4 cell counts and increased risk of mortality. Two years later, he reported that vitamin A deficiency among pregnant HIV positive women in Malawi was associated with increased risk of mother-to-child HIV transmission (32% among deficient women vs 7% among women with normal levels) and higher infant mortality. Similarly, a U.S. study found that vitamin A-deficient women were about five times more likely to transmit HIV to their babies. Some studies have found vitamin A deficiency to be associated with greater vaginal shedding of HIV and higher levels of virus in breast milk -- although Fawzi's study described above actually found a significantly higher rate of mother-to-child transmission via breast-feeding in women given vitamin A supplements.
Several large controlled studies looking at supplementation with vitamin A or beta-carotene (a vitamin A precursor) for HIV positive pregnant women in parts of Africa where frank deficiency is common, however, have failed to detect decreased rates of mother-to-child transmission; results have been mixed concerning reductions in miscarriages, premature births, and infant morbidity and mortality. In Fawzi's Tanzanian study, vitamin A alone did not produce outcomes significantly different from those seen in the placebo arm, and adding vitamin A to the multivitamin seemed to reduce its beneficial effects. Since the benefits are unclear and high doses can cause liver toxicity and other problems, most experts do not recommend vitamin A supplementation -- beyond the amount found in a typical multivitamin pill -- for people with HIV/AIDS.

Vitamin C
In laboratory studies, vitamin C has been shown to inhibit viral replication in vitro; it also plays an important role in tissue repair. Thus, it is not surprising that megadoses of this vitamin have been touted as a cure for everything from the common cold to cancer to HIV/AIDS. Controlled clinical trials comparing vitamin C to placebo for the treatment of colds and flus have yielded mixed results, and the data have been even less promising concerning HIV disease. While vitamin C deficiency does appear to impair various aspects of the immune response, research has not provided evidence that supplementation delays HIV disease progression or improves survival.

Vitamin E
Vitamin E plays a role in metabolism and proper immune function, and laboratory studies suggest it has an antiviral effect. For example, Alonso Heredia, PhD, from the University of Maryland and colleagues reported in the May 20, 2005 issue of AIDS that addition of vitamin E to cell cultures from 10 HIV positive individuals significantly reduced HIV production, as indicated by p24 antigen levels. The authors suggested that supplementation might slow HIV replication enough to inhibit the emergence of drug-resistant virus in resting cells and to delay viral rebound after treatment interruption. But while low (or decreasing) levels of vitamin E have been linked to CD4 cell declines and HIV disease progression, this does not imply causality.
The jury is still out on the benefits and risks of high-dose vitamin E supplementation, but data from recent large studies in the HIV negative population do not look good. In the Women's Health Study (a primary prevention trial that included nearly 40,000 healthy, HIV negative women), subjects randomly assigned to receive 600 IU of vitamin E every other day not only did not have reduced rates of cancer or cardiovascular disease relative to women in the placebo arm, but actually showed a nonsignificant increase in total mortality. Results of a meta-analysis of 19 clinical trials with a total of nearly 136,000 subjects published in the January 4, 2004 Annals of Internal Medicine led authors Edgar Miller, MD, and colleagues to conclude that, "High-dosage [400 IU or more daily] vitamin E supplements may increase all-cause mortality and should be avoided." In the absence of large controlled studies in the HIV positive population, the same advice is sound for people with HIV/AIDS as well.

Selenium
The trace element selenium -- also known to play a role in proper immune function -- has received considerable attention as a treatment for HIV/AIDS and a variety of other diseases. Some in vitro research indicates that HIV requires selenium in order to replicate. A study of 125 HIV positive injection drug users by Marianna Baum, PhD, and colleagues from the University of Miami (published in 1997) revealed that after adjusting for various factors including CD4 cell count, selenium deficiency was significantly associated with increased mortality. "When all nutrient factors that are associated with survival are considered together," Baum concluded in a later review article, "only selenium deficiency is a significant predictor of mortality." And in a study of 670 HIV positive pregnant women in Tanzania (reported in the June 1, 2005 issue of JAIDS), Roland Kupka, DSc, from Harvard School of Public Health and colleagues found that low plasma selenium levels were associated with increased risk of miscarriage, infant death, and mother-to-child HIV transmission.
But the fact that low selenium levels are linked to worse disease progression does not necessarily mean supplementation will improve matters. HIV nutrition expert Mary Romeyn, MD, has reported anecdotal evidence that selenium supplementation leads to clearance of thrush. On the other hand, while low selenium levels were linked to increased likelihood of cervical dysplasia (precancerous cell changes) among HIV positive women in one study, selenium supplements did not reduce the risk.

And, as reported in the December 15, 2004 issue of JAIDS, Scott McClellend, MD, from the University of Washington and colleagues found that in a study of 400 nonpregnant HIV positive women in Kenya, supplementation with a multivitamin plus selenium led to increased vaginal shedding of HIV, which has implications for sexual and perinatal transmission. Among women who started out with normal selenium levels, those who received supplements were more than twice as likely to shed HIV in their vaginal secretions and had higher vaginal HIV viral loads than women who received a placebo; a similar effect was not seen, however, in selenium-deficient women brought up to normal levels. While supplementation resulted in higher CD4 and CD8 cell counts, the authors concluded that, "The potential benefit of micronutrient supplementation in HIV-1-seropositive women should be considered in relation to the potential for increased infectivity."

Zinc
Zinc deficiency has been linked to impaired immune function and supplementation has been suggested as a treatment for people with HIV/AIDS, but studies to date have produced conflicting results. While some suggest that zinc enhances the body's ability to fight HIV and improves disease symptoms, others have found it has a detrimental effect. In one study of injection drug users, lower zinc levels were associated with reduced CD4 cell counts, but this does not necessarily mean one caused the other. In an early nutritional survey of nearly 300 HIV positive men followed for seven years, high doses of zinc were associated with faster HIV disease progression. Some researchers have hypothesized that this may be related to the fact that HIV requires zinc-containing structures called "zinc fingers" to produce functional viral progeny.
More recently, Raziya Bobat, MD, and colleagues reported in the November 26, 2005 issue of The Lancet that in a randomized, placebo-controlled trial of 96 HIV positive South African children aged six months to five years, zinc supplementation for six months reduced the incidence of diarrhea and pneumonia, and did not appear to promote viral replication. Given the degree of uncertainty, most experts do not recommend zinc supplementation beyond the amount contained in a multivitamin and mineral pill.

Antioxidants
Vitamin C, vitamin E, selenium, and zinc act as antioxidants, helping prevent cell damage caused by highly reactive free radicals (oxidative stress). While free radicals play a role in immune defense against invading pathogens, they can also harm surrounding cells. Research has shown that people with HIV and other chronic infections have higher levels of free radicals, which promote viral replication. Conversely, antioxidants appear to reduce oxidative stress, inhibit HIV activity, and possibly slow HIV disease progression. Antioxidants may also reduce liver fibrosis in people with hepatitis B or C and protect the liver from toxicity as it metabolizes drugs.
The body manufactures certain antioxidants as needed, but this process requires adequate amounts of several nutrients. Studies suggest that a major intracellular antioxidant, glutathione, may help reduce the rate of HIV disease progression. Nutrients that help raise glutathione levels include selenium, alpha-lipoic acid, N-acetyl-cysteine (NAC), acetyl-L-carnitine, L-glutamine, and coenzyme Q10. In one small study, high-dose NAC supplementation led to decreased HIV viral load. There have been several case reports and small studies in which supplementation with antioxidants or precursors including NAC, acetyl-L-carnitine, and coenzyme Q10 seemed to counter lactic acidosis (a sign of mitochondrial toxicity) related to antiretroviral therapy. What's more, Andrew Hart, MD, and colleagues from the Royal Free and University College Medical School reported in the July 23, 2004 issue of AIDS that acetyl-L-carnitine supplements helped reverse nerve damage and alleviated the pain of peripheral neuropathy associated with certain NRTI drugs.

But antioxidant supplements may also have deleterious effects. In a small pilot study by Grace McComsey, MD, and colleagues from Case Western Reserve University (reported in the August 15, 2003 issue of JAIDS), while supplementation with vitamin C, vitamin E, and NAC slightly reduced elevated LDL cholesterol levels and abdominal fat accumulation in 10 subjects with HIV-related lipodystrophy, the antioxidants also raised blood glucose levels and worsened insulin resistance. "We should never assume that high doses of vitamins are safe," the authors cautioned. "They are not safe until clinical studies prove them to be safe."

Omega-3 Fatty Acids
Omega-3 fatty acids, found in cold-water fish such as salmon and herring, have been associated with reduced cardiovascular disease risk in the general population; one study of more than 4,700 adults over age 65 showed that eating fish 3-4 times per week was associated with a 30% reduction in congestive heart failure. In the November 15 issue of CID, David Wohl, MD, from the University of North Carolina at Chapel Hill and colleagues reported that omega-3 may also help address one cardiovascular risk factor in people with HIV/AIDS. In this open-label study, 52 HIV positive individuals on HAART with fasting triglyceride levels above 200 mg/dL were randomly assigned to receive either omega-3 fish oil supplements (eicosapentaenoic acid and docosahexaemoic acid) plus nutritional counseling or else nutritional counseling alone. After 16 weeks, subjects receiving fish oil supplements experienced a 19.5% reduction in fasting triglyceride levels, compared with a 5.7% decrease in the counseling-only arm (though seemingly substantial, this difference was not statistically significant). However, LDL cholesterol levels increased by 22.4% in the fish oil arm, while remaining stable in the counseling-only arm; HDL levels did not change in either group. The authors acknowledged that "whether this increase [in LDL] attenuates any benefit in lowering triglyceride levels is unclear."

Special Supplements
Various functional supplements have been developed to augment levels of particular compounds thought to have specific beneficial effects. For example, two small studies presented at the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV in November 2005 showed that a supplement called NucleomaxX -- a sugar cane extract containing the nucleoside uridine -- helped reverse lipoatrophy in individuals taking NRTIs. Jussi Sutinen, MD, and colleagues from Finland reported than in a study of 20 patients taking d4T or AZT (zidovudine, Retrovir), those taking NucleomaxX three times daily for 10 days gained significantly more arm and leg fat (about 900 grams) than subjects taking placebo; the NucleomaxX group also gained visceral abdominal fat. Likewise, McComsey reported that both patients and their physicians reported significant improvement in lipoatrophy in a study of 14 subjects taking d4T who received NucleomaxX three times daily every other day for 16 weeks. (An open-label Phase II study of NucleomaxX for lipoatrophy is currently enrolling; see "Open Clinical Trials," in this issue).

Good Nutrition is Not a Cure for HIV
While supplementing a range of micronutrients may contribute to improved health, this is not to suggest that nutritional supplements alone can take the place of HAART. A few years ago, South African Health Minister Manto Tshabalala-Msimang raised a furor when she suggested that people with HIV/AIDS should consume garlic, lemon, and olive oil, while her government was resisting efforts to expand access to antiretroviral therapy. This past May, UNAIDS director Peter Piot, MD, blasted vitamin entrepreneur Matthias Rath, who placed ads in South African newspapers promoting vitamins as a treatment for AIDS, claiming that antiretroviral drugs are toxic and cause birth defects. "Vitamins are no cure or treatment for AIDS," stated Piot, "and anybody who claims the contrary is a charlatan."

Nevertheless, according to World Health Organization Director-General Jong-Wook Lee, greater attention must be paid to the nutritional needs of people with HIV/AIDS in the developing world. "We do know that sound nutrition helps maintain the immune system, increases body weight, and boosts energy levels," he said at an April conference in Durban. "Most of the 30 million HIV-infected people in Africa don't even have secure access to the basic nutrients any human being needs to live a healthy life."

More Is Not Always Better
With all this conflicting data, it can be difficult for HIV positive people to make informed decisions about supplements. The bottom line, according to Judith Nerad, Mary Romeyn, and colleagues in the April 2003 CID special issue: "[T]here is little documentation in the literature that supplementation beyond what is recommended has had any impact on clinical outcome." But, "[i]f a patient's vitamin or mineral status is deficient, supplementation is clearly necessary."
People with HIV/AIDS commonly have subtle nutritional deficiencies, and research to date has shown that daily multivitamin use is safe and at least potentially beneficial in this population. Different experts have suggested various supplementation regimens. For example, Romeyn -- in her book Nutrition and HIV: A New Model for Treatment -- suggests a basic regimen that includes:

a multivitamin, without extra iron, twice daily;

a trace element supplement once daily;

an antioxidant supplement once daily.
Others, such as nutritionist Margaret Davis, RD, recommend only the multivitamin, plus increased consumption of fruits and vegetables.

As previously noted, nutritional needs vary widely from person to person, and there is no one diet or supplement regimen appropriate for all people with HIV/AIDS. Further, the presence of a nutrient deficiency does not necessarily mean supplementation is the solution, since poor absorption, underlying infections, metabolic changes, or hormone imbalances could be contributing to the problem.

When using supplements, do not take more than the recommended dose on the label unless advised to do so by a knowledgeable healthcare provider. As some of the studies discussed above illustrate, more is not necessarily better. A recent case underscores this warning. As reported in the September 2005 International Journal of STD and AIDS, an HIV positive man in London developed severe liver inflammation with skyrocketing ALT levels after taking more than a dozen dietary supplements, many at high doses -- as much as 67 times the recommended daily value; fortunately, once he stopped taking the supplements, his liver function returned to normal.

Certain vitamins and minerals (including the fat-soluble vitamins A, D, and E) can be toxic at high doses, and they may cause deleterious effects even at lower doses beyond what is provided in a typical multivitamin pill. Remember that "natural" does not necessarily mean "safe." Beware of any supplement touted as a "cure" for a range of ailments -- if something sounds too good to be true, it probably is. Verify that health claims are supported by reliable research. Some supplements may not be harmful, but simply a waste of money. Seek medical advice before starting a new supplement or beginning any unusual diet. Tell healthcare providers about any use of supplements (as well as over-the-counter medications, recreational drugs, and herbal remedies), since these can potentially interact with antiretroviral drugs.

Eat Right for Life
Nutritional management should be a regular part of HIV/AIDS care. Even if an HIV positive person has no obvious nutritional problems such as wasting, a healthy diet can still help stave off illness and improve quality of life. But, as Tang and colleagues noted in their review, dealing with nutritional issues "may not be part of the traditional care or thought process of the HIV care provider." A registered dietitian (RD) who has experience working with people with HIV/AIDS can be an invaluable resource.
The American Dietetic Association recommends a baseline nutritional and body composition assessment soon after HIV diagnosis. Follow-up assessments should be conducted at least once annually for asymptomatic individuals with well-controlled HIV disease, and every few months for patients with AIDS or known nutritional problems. Tasmin Knox, MD, from Tufts recommends anthropometric measurements of body composition (see "Weights and Measurements" above for an explanation of various methods); laboratory tests of protein and micronutrient levels in the blood; tests of metabolic parameters such as blood lipids, blood glucose, and liver enzymes; and clinical assessment of eating patterns, supplement use, functional status, physical symptoms, and psychological or socioeconomic issues that may impede adequate nutrient intake. Some experts recommend that people keep a daily diary of everything they eat, along with any dietary problems they encounter.

Once such an assessment is complete, promptly address any underlying problems -- such as infections, hormone imbalances, or metabolic disorders -- that may be interfering with proper nutrition. The next step is to develop an appropriate, individualized nutrition plan. Seniors, growing children, pregnant or breast-feeding women, and people with active OIs are among the many groups that have special nutritional needs. While supplements can offer important benefits, they do not replace a well-balanced diet. When it comes to good nutrition, there is no "quick fix." It's better to develop long-term healthy eating habits, such as cutting back on saturated fat and consuming more fruits, vegetables, and whole grains. But set realistic goals: it's fine to splurge occasionally if one normally adheres to a healthy diet. Fortunately, small changes in eating habits can often make a big difference in terms of health.

Since many people with HIV/AIDS use dietary supplements in addition to HAART, it's crucial to learn more about how nutritional supplementation impacts HIV disease and vice versa. According to Tang and colleagues, areas ripe for further research include the role of micronutrient supplementation in people with well-controlled HIV disease, whether micronutrients can enhance CD4 cell responses, the role of antioxidants in countering increased oxidative stress due to HIV infection or its treatment, whether micronutrient supplementation can help reduce morbidity associated with coinfections such as hepatitis B or C, the role supplements might play in addressing metabolic manifestation such as lipodystrophy and bone loss, and the appropriate doses of supplements for HIV positive people at various stages of disease.

"Attempts to improve dietary quality and micronutrient status may play an overall role in maximizing health for the HIV-infected individual, particularly in undernourished populations," Tang and colleagues concluded, "and may also play a role in the more subtle management of HIV infection in the future."

Liz Highleyman (liz@black-rose.com) is a freelance medical writer and editor based in San Francisco.

 
AddMe - Search Engine Optimization
Changing LINKS
Changing LINKS